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This thesis consists of the following two articles, formatted in the style used by 
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Paper I, Evolutionary Timeline of Genetic Delivery and Gene Therapy, found on 
pages 4-64, has been submitted to Current Gene Therapy.
Paper II, DOX-loaded DNA Origami Triangle Uptake and Cytotoxic Effects in 




A review of gene delivery methods and gene editing methods, as well as original 
research utilizing DNA as a delivery vehicle is presented in the following thesis. 
Thousands of diseases have been linked to genes. Gene therapy, either delivering 
therapeutic genes or editing DNA bases, has arisen as a treatment option with the 
potential to cure diseases, rather than just ease symptoms. Genes and editing tools need to 
be delivered to cells for these therapies to be effective and many techniques have been 
developed to address the issue of delivery. Nonviral and viral methods have been used to 
deliver nucleic acids and several different protein systems have been employed to edit 
genes. Gene therapy will continue to evolve as delivery are improved. Along with being 
delivered as a therapeutic molecule, DNA has been investigated as a carrier itself. DNA 
origami, have been utilized to deliver chemotherapies to breast cancer. Globally, millions 
of women are affected by breast cancer each year. DNA origami was analyzed as a 
carrier for the chemotherapy Doxorubicin (DOX) in two triple negative breast cancer 
(TNBC) cell lines, a type of breast cancer with few treatments. The killing efficiency and 
uptake of DOX loaded into a model DNA origami triangle (DOX-DNA-T) were 
elucidated. Inhibition of various pathways revealed DOX-DNA-T was internalization by 
multiple energy-dependent pathways. DOX-DNA-T altered the subcellular localization of 
DOX and increased the concentration of DOX inside cells. A delayed killing was 
observed with DOX-DNA-T compared to free DOX, but the carrier was able to modulate 
the toxicity between cell lines. Overall, DNA delivery is able to treat various disease 
conditions and DNA origami is an interesting carrier for therapeutics.
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Here, a review of DNA delivery and genome editing techniques are presented, as 
well as original research over the uptake and cytotoxicity of DNA nanostructures, also 
known as DNA origami. The original research has the potential to improve the 
therapeutic efficacy of DNA origami as a carrier system.
Predisposition to and development of certain diseases have been linked with 
specific genes [1]. Many genetic diseases are due to simple mutations in one gene, such 
as sickle cell anemia, cystic fibrosis, and Huntington’s disease [2-4]. Historically, genetic 
diseases have not been able to be cured, with symptoms only being able to be modulated 
with drugs. Traditional protein and small molecule drugs used to treat genetic diseases 
often have pharmacokinetic issues [1]. However, with current technology, these diseases 
can be cured by supplying diseased cells with functional genes or correcting a mutated 
gene.
DNA, the material encoding all of instructions required for life, has been utilized 
as a therapeutic molecule and more recently to deliver other therapies to cells. Delivery 
of compounds across target cell membranes is essential for function inside cells. Nucleic 
acid and therapeutic molecule delivery have been achieved using a variety of different 
methods. However, delivery methods are constantly improving and the optimal carriers 
for different systems are still sought.
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Many methods have been developed in an attempt to deliver therapeutic nucleic 
acids or genome editing tools for genome correcting, each with varying effectivity, 
cytotoxicity, immunogenicity, and sustainable effects [1, 5]. Delivery strategies fall into 
two main categories: viral and nonviral. Nonviral methods rely on physical 
(microinjection, bioballistics, hydrodynamic force, ultrasonic nebulization, and 
electroporation) or chemical (calcium phosphate co-precipitation, lipofection, and cell- 
penetrating peptides) cell membrane infiltration [5-13]. A variety of viruses have also 
been used for delivery and to overcome the cell membrane, including adenoviruses, 
adeno-associated viruses, and retroviruses [14]. Zinc finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs), and CRISPR-Cas systems have 
been utilized to target and correct defective genes after delivery into cells [1]. These 
subjects are further reviewed in Paper I.
Our understanding of DNA has allowed us to develop methods to reprogram cells, 
including technologies that can edit genes. Our ability to program DNA also gave rise to 
a method to fold the nucleic acid into new and accurate shapes in 2006 [15, 16]. Most 
nanostructures and nanoparticles used for delivery are not programmable; it can be 
difficult to control their size uniformly and their shapes are often limited to spheres [17]. 
The geometry of nanostructures can affect their biodistribution, their movement through 
fluids, and their cellular internalization [17]. The use of DNA allows for high precision 
design of geometry and easy functionalization [15, 18]. The design and flexibility of 
DNA nanostructures, or DNA origami, is optimal for a drug carrier system. However, 
degradation in vivo by endogenous endonucleases is a large concern [16].
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DNA origami has been utilized for chemotherapy delivery and cancer treatment. 
Millions of women are diagnosed each year with breast cancer [19]. Triple negative 
breast cancers (TNBCs), a particularly devastating form of breast cancer [20, 21], lack 
treatment options because they do not respond to frequently used cancer therapies [22]. 
Often, harsh nonspecific chemotherapies are used in combination with surgery [21, 23, 
24]. One such chemotherapy is Doxorubicin (DOX) [25]. DNA origami has been used to 
delivery DOX to cancer cells, as DOX intercalates into the DNA double helix [25, 26]. 
These nanostructures have been shown to have high passive accumulation within tumors 
and increase drug delivery to the tumor site [18, 27]. Using nanocarriers to directly 
deliver drugs to tumors can increase retention time to combat drug resistance and can 
reduce overall toxicity in patients [15, 28, 29].
Although DNA origami have been used for the delivery of chemotherapeutic 
drugs, their exact uptake mechanism is not entirely understood, an important aspect 
which influences drug delivery efficacy. Paper II discusses original research utilizing 
DNA origami to deliver DOX to breast cancer cells. The killing efficiency, uptake 
mechanism, and subcellular localization of a model DNA origami triangle were 
determined in two TNBC cell lines. It was found that DNA nanostructures facilitate drug 
entry, have delayed toxicity and release of drugs, and are internalized by energy- 
dependent pathways. Localization was time- and concentration-dependent.
4
PAPER
I. EVOLUTIONARY TIMELINE OF GENETIC DELIVERY AND GENE
THERAPY
Natalie J. Holla, Han-Jung Leeb, and Yue-Wern Huanga*
aDepartment of Biological Sciences, College of Arts, Sciences, and Business, Missouri 
University of Science and Technology, Rolla, MO 65409, USA;
bDepartment of Natural Resources and Environmental Studies, College of Environmental 
Studies, National Dong Hwa University, Hualien 97401, Taiwan
ABSTRACT
There are more than 3,500 genes that are being linked to hereditary diseases or 
correlated with elevated risk of certain illnesses. As an alternative to conventional 
treatments with small molecule drugs, gene therapy has arisen as an effective treatment 
with the potential to not just alleviate disease conditions but also to possibly cure them 
completely. In order for these treatment regimens to work, genes or editing tools intended 
to correct diseased genetic material must be efficiently delivered to target sites. There 
have been many techniques developed to achieve such a goal. In this article, we 
systematically review a variety of gene delivery and therapy methods that include 
physical methods, chemical and biochemical methods, viral methods, and genome 




Hereditary diseases and disease predisposition have been associated with 
particular genes. Over 3,000 genes have been linked to hereditary illnesses and around 
500 have been identified that increase risk for certain diseases [1]. For example, cystic 
fibrosis is a recessive illness occurring in individuals carrying two copies of a mutant 
CFTR (cystic fibrosis transmembrane conductance regulator) gene [2]. Patients carrying 
two recessive P-globin genes with a single base substitution present with sickle cell 
anemia [3] and patients with one copy of a dominant mutation in the huntingtin (HTT) 
gene develop Huntington’s disease [4]. Historically, these diseases are not curable and 
symptoms can only be managed. Some treatments, such as proteins and small molecules, 
are difficult to apply due to bioavailability, stability, specific targeting, and other 
pharmacokinetics issues [1].
The idea of gene therapy first arose in the 1970s [5]. Initial applications focused 
on gene replacement therapy to treat inherited disorders by supplying target cells with a 
copy of a normal gene. In the last fifty years, these delivered treatments have advanced to 
include protein-coding cDNA sequences and non-coding small nucleic acids that regulate 
a broad spectrum of cellular behaviors and functions. Both of which are becoming 
mainstream therapies and hold tremendous potential in revolutionizing medicine. In 
addition to replacing a target gene, protein-coding cDNAs are being widely used to 
manipulate neurotrophic factors in neurodegenerative diseases such as Parkinson’s and 
Alzheimer’s diseases, modulate regulatory proteins that involve cell survival and 
apoptosis of cancer, produce angiogenic factors in cardiac ischemia, and immune-
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modulate HIV and other immune diseases [6]. In the past decade, non-coding small 
nucleic acids represent a new shift of paradigm in gene therapy. Non-coding nucleic acids 
include oligonucleotides, catalytic RNAs or DNAs, antisense RNAs, and aptamers. These 
non-coding nucleic acids have been used to completely silence or partially regulate 
functions of certain genes to mitigate disease severity or progression in cancer, 
neurodegenerative diseases, and cardiovascular diseases, among others [7-9].
Missing genes may be added into cells using various techniques in order to 
combat illnesses [10-13]. Genome-editing technologies may be able to edit or replace 
defective genes and eliminate genetic diseases all together [1]. Genome editing is the key 
to advancing treatment of inheritable diseases and human medicine. In theory, these 
techniques sound simple. In reality, the development of genome editing is sophisticated 
and has experienced numerous setbacks. One of the most notable setbacks being the 
death of Jesse Gelsinger in 1999, the first death associated with gene therapy [14]. 
Gelsinger took part in an experimental gene therapy trial to treat a rare metabolic disorder 
known as ornithine transcarbamylase (OTC) deficiency. His body overreacted to the viral 
vector used and he died after multiple of his organ systems failed. His death shocked the 
research community and no gene therapy clinical trials relating to OTC were proposed 
until 2016 [15]. This clinical case is a manifestation that efficacy and safety are equally 
important in developing gene therapies.
In vitro and in vivo DNA deliveries are key to numerous aspects of life science 
research which include, but are not limited to, discovery of fundamental principles in 
biology (e.g., gene structure, regulation, and function), understanding the nature of 
human diseases (e.g., genetic defect and correction), and biomedical applications (e.g.,
gene therapy, drug delivery, and DNA vaccination). One of the major obstacles in DNA 
delivery is the mammalian cell membrane due to its non-polar and hydrophobic nature. 
Over the course of evolution, cells have survived by making their membranes selective. 
On one hand, selectivity allows for the efficient passage of nutrients, minerals, and other 
essential materials into cells for growth and removal of cellular wastes [16]. On the other 
hand, selectivity helps fend off harmful materials from entering into cells. Polyanions, 
such as nucleic acids, are poorly internalized but can be delivered into cells using various 
carriers and methods. Before the benefits of DNA therapy can be relished, inefficiency in 
delivery must be addressed.
Delivery of nucleic acids into mammalian cells can be generally divided into two 
main strategies: viral and nonviral delivery. Nonviral delivery tools can be based on 
physical methods or various classes of chemicals, such as cationic lipids, polymers, 
peptides, or carbohydrate analogs [17]. Physical nonviral methods discussed in this 
review encompass microinjection, bioballistics, hydrodynamic force, ultrasonic 
nebulization, and electroporation. Chemical and biochemical nonviral methods include 
calcium phosphate co-precipitation and membrane infiltration mediated by artificial 
lipids and peptides. Importantly, small delivery peptides, termed cell-penetrating peptides 
(CPPs), have gained great interest among these nonviral tools. Viral delivery of genetic 
material takes advantage of the natural life cycle of viruses, using viruses with modified 
or synthetic genomes to inject therapeutic genes into cells. Depending on the virus used, 
delivered genes may exist as a plasmid inside cells or be integrated into the host genome. 
Viral vectors discussed here include adenovirus, adeno-associated virus, gamma-
7
retrovirus, and lentivirus.
Each delivery method has its benefits. Viral methods are efficient, but may cause 
adverse immune responses. Nonviral gene transfer is likely to be nonimmunogenic, but 
often suffers from lower transfection rates and toxic carriers. Nonviral methods of 
delivery also are often limited by transient transfection [5], with expression of delivered 
genetic material often only lasting for a short period due to low integration rates [18].
This is due to the low chance that plasmid DNA can enter the nucleus, with the only time 
period to enter being when nuclear membrane is destabilized (e.g., during replication) 
[19]. Integrating viral vectors have higher rates of transient transection than nonviral 
vectors; however, it should be noted that integration at random locations in the genome 
can result in mutagenesis and oncogenesis [1]. Nevertheless, the importance of viral 
vectors as a DNA delivery tool cannot be overlooked, as they have been a pivotal partner 
in revolutionary genetics, cell biology, molecular biology, and medical discoveries.
Genome editing, also known as gene editing, is defined as a group of technologies 
used to change an organism's genome according to the US National Institutes of Health 
(NIH) [20]. These technologies allow genetic material to be artificially added, removed, 
or altered at particular locations in the genome. Many strategies are currently available 
for programmable and targeted genome editing, including zinc finger nucleases (ZFNs) 
and transcription activator-like effector nucleases (TALENs). The clustered regularly 
interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 
system is a next-generation genome editing technology, which is originally based on a 
system used by bacteria and archaea to combat recurrent viral infections.
The number of clinical trials involving gene therapy has steadily increased over 
the years, with approximately 2,600 trials up until 2017 [21]. The majority of clinical
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trials use viral vectors, including adenovirus (20.5%), retrovirus (17.9%), adeno- 
associated virus (7.6%), lentivirus (7.3%), vaccinia virus (6.6%), poxvirus (4%), and 
herpes simplex virus (3.5%). Naked DNA (16.6%), often in combination with 
electroporation, and lipofection (4.4%) are the most common nonviral methods used in 
clinical trials [21]. It should be kept in mind that certain types of delivery methods will 
become more or less popular as techniques are refined, efficiency is fine-tuned, or new 
technologies are developed.
Here, historically important discoveries for gene transfection and gene editing 
methods are discussed, as well as method advantages and disadvantages. A timeline of 
significant milestones in gene delivery and gene therapy is provided in Figure 1.
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Figure 1. Significant milestones in gene delivery and gene therapy. Adeno-associated 
virus (AAV), adenovirus (AV), cell-penetrating peptide (CPP), zinc finger nuclease 
(ZFN), transcription activator-like effector nuclease (TALEN), clustered regularly 
interspaced short palindromic repeats (CRISPR), CRISPR-associated protein 9 (Cas9).
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2. PHYSICAL METHODS
Physical methods of gene delivery act by directly penetrating or compromising 
the cell membrane in order for nucleic acids to pass into cells. They are some of the 
earliest methods of gene delivery, though cell viability and transfection efficiency for 
many of the techniques is lacking. Physical methods are diagramed in Figure 2.
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Figure 2. Physical methods of gene delivery. The cell membrane is compromised by 
different means in order to facilitate nucleic acid internalization. Microinjection, 
bioballistics, hydrodynamic force, ultrasonic nebulization (a.k.a. sonoporation), and 
electroporation are common physical delivery techniques.
2.1. MICROINJECTION
Microinjection, or the direct injection of genetic material into cells [22], was one 
of the first methods used to transform cells. It is a simple method, but delicate and
therefore difficult to carry out [23]. It does not rely on a carrier for DNA, making it not 
immunogenic or toxic [24]. Nucleic acids are injected into a single cell using a needle. 
DNA can then be localized to the nucleus after injection into the cytoplasm or be directly 
injected into the nucleus to transform a cell. Microinjection is perfect for cloning and 
single cell manipulation. The first cases of microinjection date back to 1911, when 
Marshall Barber used the technique to clone bacteria [25]. The first animal clones were 
created by transferring the whole nucleus of one embryonic frog cell to the oocyte of 
another in 1952 [26]. However, the older the transplanted nuclei, the less likely a normal 
tadpole was to develop. In 1974, microinjection was used to create the first transgenic 
animal by injecting viral DNA into a mouse blastocyst [27]. In the 1990s, regional 
transfection of tissue by DNA injection was demonstrated [18]. However, it was not until 
1997 that adult cells were able to be used to create viable clones, resulting in the famous 
Dolly the sheep [26, 28]. Using small amounts of DNA, the technique is cost effective
[29] . While efficiency is high when DNA is injected directly into the nucleus, 
transformation can be low if DNA is degraded by cytoplasmic nucleases [23]. A mouse 
cell line showed expression in 50 to 100% of cells given genes by direct nuclear injection
[30] . The process can be slow and tedious when many cells are to be transformed [22].
On the other hand, the method is not dependent on cell type, so it can be used with cells 
that are difficult to transform [24]. Attentional benefits to this technique are the precise 
control of the amount of genetic material passed to cells and the surety that most cells 
treated will receive genetic material [31], with the nucleus receiving around 90% of fluid 
directly injected [30]. More recent advances in microinjection techniques have led to the 




One forceful method of genetic transduction is bioballistics. In this technique, a 
“gun” is used to accelerate metal particles covered in genetic material through cells [18]. 
Any particles that travel through the cells have a chance to leave behind the nucleic acids 
that were on the surface of the metal. Tungsten, silver, and gold particles are most 
commonly used as the carrier and are accelerated using pressurized inert gases or electric 
charges [18, 33]. The size and speed of the particles play a major role in the gene transfer 
efficiency [33]. Klein et al. first applied this method using plant cells in 1987 [18, 34]. 
The group used tungsten particles coated in nucleic acid and accelerated them using a 
gunpowder blast [34]. A downside to bioballistics is that if a cell is hit with a large 
number of particles, viability is reduced [34]. Low accuracy, tissue damage, and low 
efficiency [35], in part due to high DNA degradation [36], are also issues. Only around 3 
to 15% of cells targeted with bioballistic gene transfer show high expression [35]. The 
cost of materials is also high [23], which can be a detriment to researchers if a large 
number of transformations must be performed. However, the method is relatively easy to 
carry out and stability of the carrier is not a concern [35]. The size and properties of the 
metal particles also enable them to deliver multiple or large DNA molecules that other 
methods may not [35]. A large concern from a toxicological perspective is that the 
ultimate fate of the particles is often not known [37]. Metal particles may oxidize in 
biological systems and result in unintended toxicity if they are not removed. Bioballistics 
can be applied to both organisms and cells [23]. Advances in this method resulted in the 
development of a hand-held gun, the Helios Gene Gun, which allowed in situ
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transformation more easily [36]. Xia et al. used the Helios Gene Gun to transfect the skin 
and livers of mice with bioluminescent reporter genes [38].
2.3. HYDRODYNAMIC FORCE
Hydrodynamic force uses pressure in the circulatory system to increase the 
permeability of cells [18]. The first successful application of hydrodynamic force for 
gene delivery is attributed to Budker et al. in 1998 [39, 40]. This method was designed 
for use in vivo, originally in rodents, but has been used in various animals including 
rabbits, dogs, fish, pigs, monkeys, and humans [39]. Immunogenicity and toxicity of 
carriers are not a concern as naked DNA is used in solution [41]. A solution around 8 to 
12% of the subject’s body weight is injected quickly, in 5 to 7 seconds, to achieve the 
systemic pressure needed to facilitate nucleic acid uptake [39, 41]. Transfection rate is 
highly dependent on injection volume, injection time, and DNA concentration [41]. 
However, large injection volumes have been deemed unsafe for people [18] as too much 
fluid in the circulatory system can lead to cardiac arrest [39]. Along with this, large 
volumes of DNA may be difficult to cultivate for each individual injection. Due to the 
need for a pressurized system, this method is not applicable to individual cells [39]. 
Transfection also often accumulates in specific organs, especially the liver [41, 42]. Lui 
et al. showed that 40% of the hepatocytes of mice injected with plasmid DNA via the tail 
vein expressed a reporter gene, while the lung, kidney, spleen, and heart all had 
expression levels less than 1000-fold of the liver expression [41]. This makes the 
technique particularly useful for gene expression in specific organs, but not useful if 
expression is desired elsewhere. This method has been used to develop a mouse model of
hepatitis B infection, which normally is unable to infect rodents, by forcing viral 
genomes into mice hepatocytes [39, 42, 43]. One technique used to decrease injection 
volumes in animals larger than rodents is to use a balloon catheter to isolate a particular 
organ so pressure can be increased locally [44]. When balloon catheters where used to 
isolate the liver of pigs, injection volumes could be reduced from 10% to 1.25% of the 
individual’s body weight [44]. This also allows organs and tissues with lower affinity for 
transfection in whole body injections to be targeted.
2.4. ULTRASONIC NEBULIZATION
Fecheimer et al. were the first to demonstrate cells transfection using ultrasonic 
nebulization, also known as sonoporation, in 1987 [45, 46]. This method relies on the 
formation of pores in cell membranes by ultrasonic waves [33]. The intensity and 
frequency of the ultrasonic waves used, as well as tissue type, determine the biological 
effects [18]. Typically, ultrasound in the 2 to 20 MHz range, with maximum intensities 
limited to 720 mW/cm2 by the US Food and Drug Administration (FDA) [47], is used for 
medical imagining [48]. However, only 1 to 3 MHz, with higher intensities ranging from 
0.5 to 2.5 W/cm2, are used for gene delivery [18]. Initial studies demonstrated 
sonoporation using 20 kHz [48]. Ultrasound can result in heating and cavitation within 
tissues, depending on the intensity of the waves [48]. Cavitation can concentrate 
ultrasonic energy and occurs when ultrasound waves produce and interact with 
microbubbles in solution, resulting in wave deflection, resonance frequency vibration of 
bubbles, and bubble imploding [45, 48]. Cavitation of microbubbles causes mechanical 
damage in cells and tissues, which can be observed as pore formation or cell lysis [48].
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The utilization of ultrasound in gene delivery was dramatically improved by combining 
ultrasound wave application with injected microbubbles in the mid-1990s [18, 45]. The 
addition of microbubbles “lowers the threshold for cavitation,” [45], as bubbles do not 
need to be generated. Injected microbubbles are gas-filled vesicles with a shell that can 
be composed of various substances, including phospholipids, proteins, and polymers [18], 
and can vary between 1 to 10 pm in diameter [45]. Clinically, microbubbles are routinely 
used as contrast agents for ultrasonic imaging [45]. During gene transfection, DNA can 
be injected as a solution or integrated into microbubbles [33]. Ultrasound is applied to a 
target location, limiting where cavitation occurs. Sonoporation has potential for in vivo 
applications as it is noninvasive [45]. Ultrasound and site-injected phospholipid 
microbubbles were able to successfully transfer a luciferase reporter gene into mouse 
muscle tissue [49]. However, despite the potential applications, ultrasound has not been 
applied for clinical gene therapy, due to low efficiency and high cell death [45]. Primary 
rat cells treated with ultrasound only showed a 2.4% transient transfection rate and a 
0.3% stable transfection rate, with only 50% of cells surviving the process [50].
2.5. ELECTROPORATION
It has been known that electricity alters membrane permeability since the 1960s 
[18]. Electric fields can result in the formation of membrane pores, cell fusion, and cell 
movement [51]. When electric pulses are applied to cells, the pores formed allow nucleic 
acids to move across the plasma membrane [51]. The electric field causes the cell 
membrane to polarize and breakdown temporarily [33]. Timing and intensity of the 
electric pulses, as well as buffers, affect the delivery of nucleic acids [51].
15
Electroporation parameters must be optimized for individual cell types because if the 
intensity used is too high, cell membranes may not be able to close [51, 52]. Applying 
electric pulses to cells can result in death, in part due to membranes no being able to seal 
[22]. Different cell types are more effectively transformed with specific pulse length and 
strength [33]. It can be time consuming to determine the best buffers and electric 
intensity to use for various cell types [52]. However, the technique is useful for cells that 
are hard to transform, such as T cells, hMSC, and HUVECs, and is efficient when low 
cell viability is not a concern [51]. Electricity was first applied for genetic transformation 
in 1982 in mouse lyoma cells by Neumann et al. [53], who coined term for 
electroporation [51]. In 1991, the first in vivo transformation using electroporation was 
demonstrated with mouse skin cells [18, 54]. In this process, a target location in the body 
is injected with DNA. Electrodes are then used to apply pulses of electricity to induce cell 
membrane permeability [18]. The efficiency is dependent on the distribution of the 
electric field, which may be altered by electrode type and placement [51]. This method 
has been demonstrated locally in the testis and eyes of mice and the forebrain of zebrafish 
[51]. When DNA was directly injected into rat livers and treated with electric pulses, 30 
to 40% of hepatocytes expressed a reporter gene [55]. Additionally, Heller et al. reported 
that 20 to 30% of skin cells expressed a luciferase gene after transfection using 
electroporation [56]. However, ability to access different organs noninvasively with 
electrodes in vivo limits its applications [18].
16
17
3. CHEMICAL AND BIOCHEMICAL METHODS
Chemical and biochemical methods of gene transfection involve complexing 
nucleic acids with organic or inorganic compounds to facilitate cellular uptake. 
Complexes interact with the cell surface and cell membrane molecules to induce 
endocytosis or internalization. Chemical methods are diagramed in Figure 3.
Figure 3. Chemical methods of gene delivery. Chemical methods complex with nucleic 
acids and mediate uptake by interacting with the cell membrane. Calcium phosphate co­
precipitation, as well as peptide and lipid carriers, are commonly used chemical 
transfection methods.
3.1. CALCIUM PHOSPHATE CO-PRECIPITATION
Calcium phosphate co-precipitation was first described by Frank Graham and A.J. 
van der Eb in 1973 [22, 57]. This method utilizes the phosphates lining the backbone of
nucleic acids. A stable ionic complex is formed between the backbone phosphates and 
divalent metal cations, originally Ca2+ but Mg2+, Ba2+, and Mn2+ have also been used 
in similar co-precipitations [58]. The ion-DNA phosphate complex can be endocytosed 
by cells after coming in contact with the cell surface [22]. To form and precipitate 
complexes, phosphate buffered saline is added to a mixture of DNA and calcium chloride 
in solution [59]. Precipitates used for gene delivery usually range in size from 10 to 100 
nm [59]. The method is relatively cheap, easy to carry out [24], and benefits from the 
biodegradability of calcium phosphate [59]. It can be used with many cell types and is 
often used when transfecting large numbers of cells [24]. However, cytotoxicity is a 
concern as intracellular calcium levels are generally low [22, 59]. Increased intracellular 
calcium levels could be a particular issue for muscle cell transfection, as calcium ions 
regulate muscle contraction [60]. Ca2+ membrane pumps may be able to mitigate 
calcium toxicity by pushing excess Ca2+ outside of cells [61]. Results from calcium 
phosphate co-precipitation can be highly variable due to differences in complex size [22]. 
Transfection efficiency is controlled by the cell type and the precipitation conditions, 
including calcium chloride and DNA concentration, pH, temperature, and crystal growth 
time [59]. Smaller precipitates show higher transfection rates than larger particles [62].
As such, precipitates are not able to transfect cells if they are stored for long periods due 
to nanocrystals growing into microcrystals [33, 59]. Jordan et al. demonstrated 
transfection efficiencies of approximately 60% in CHO cells and approximately 40% in 
HEK-293 cells using small particles, but efficiencies dropped to 3 to 5% when large 
particles were used [63]. The variation in transfection efficiency between cell types is 
also apparent, as transfection efficiency in neuronal cells is generally low, ranging from 1
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to 5% [64]. Efficiency variation and low reproducibility may be due to rapid nucleation 
and growth of the particles [61]. This method is difficult to apply in vivo [22, 58], in part 
due to “poor colloidal stability and uncontrolled growth” [61]. However, calcium 
phosphate precipitates modified with polymer and lipid coatings have shown promise for 
in vivo delivery [61]. Roy et al. modified calcium phosphate precipitates with a polymer 
and a targeting ligand to increase gene delivery to liver cells in mice by 400 to 500% 
compared to unmodified particles [58].
3.2. LIPOFECTION
Gene transfection using lipids, also called lipofection, is one of the most used 
nonviral methods for genetic transfer [18]. Lipofection was developed and first 
demonstrated by Felgner et al. in 1987 [52, 65]. A variety of lipids are used in lipofection 
but most are cationic and amphiphilic, generally being composed of a hydrophilic amine 
head, linker, and hydrophobic hydrocarbon tail [66]. These lipids form micelles and 
liposomes when placed in aqueous solutions, with hydrophobic tails associating together 
and hydrophilic heads interacting with the environment [66]. Negatively charged DNA 
can be electrostatically complexed to the positively charged anime head of the lipids; the 
complexes are often referred to as lipoplexes [66]. DNA is protected from nucleases in 
the lipoplex as the nucleic acid becomes surrounded in lipids [18]. Additionally, 
positively charged heads are able to interact with the negatively charged cell membrane 
molecules, such as proteoglycans and glycoproteins, mediating internalization [18]. 
Lipoplexes can be endocytosed or can merge into the cell membrane, depending on the 
properties of the lipids and cells used [67]. Since lipids are basic components of cell
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membranes, lipofection is nonimmunogenic [66]. The lipids are easily modified to 
improve efficiency [66]. “Helper” lipids, such as dioleoylphosphatidylethanolamine 
(DOPE) or cholesterol, can be included in the lipoplex mixture to improve gene delivery 
[66]. Lipid composition and the ratios of helper lipids can be optimized to improve 
efficiency for specific cell lines [19]. Functional groups, such as polyethylene glycol 
(PEG), may also be added [66]. Transfection efficiency is influenced greatly by the size 
of the lipoplex [68]. Larger lipoplexes are more efficient at delivering DNA in vitro [69]. 
However, larger lipoplexes are cleared from the blood faster than smaller ones in vivo 
[68]. The type of lipids used, lipid and DNA concentration, and transfection media also 
affect delivery efficiency [69]. One of the most commonly used and commercially 
available lipids for transfection is lipofectamine [19, 70, 71]. Using Lipofectamine®
2000, Dalby et al. showed transfection in 20 to 30% of primary rat neurons [70].
However, lipofectamine and other lipoplexes can be toxic. For example, lipofectamine 
and several lipoplexes containing helper lipids reduced the viability of A549 and H1299 
cells by around 20% [71]. Kulkarni et al. treated primary chicken embryonic cells with 
lipofectamine and saw only 33% cell survival, with around a 50% transfection rate [19]. 
The group was able to increase survival to 85% and transfection to 90% in the same cells 
by modifying the ratios and composition of the lipids used.
3.3. CELL-PENETRATING PEPTIDES (CPPs)
3.3.1. Introduction to CPPs. CPPs, also known as protein transduction domains 
(PTDs), Trojan peptides, or membrane transduction peptides, are short peptides generally 
containing 5 to 30 amino acids [17, 72-75]. They are characterized by their remarkable
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ability to translocate through plasma membranes and enter into cells, tissues, and even 
organisms [76, 77]. CPPs possess the ability to traverse biological membranes efficiently 
in a process termed protein transduction [78]. Importantly, CPPs are capable of 
transporting numerous cargo molecules, such as DNA, RNA, oligonucleotides, 
liposomes, proteins, and nanoparticles, both in vitro and in vivo [73, 76, 77].
CPPs have very different origins and are ambiguous in many ways [17]. CPPs 
may originate from naturally occurring peptides in living organisms, chimeric peptides 
from naturally modified proteins, and synthetic peptides from design [73]. Many early 
CPPs were identified from naturally occurring protein sequences that were found to 
possess membrane-translocating properties. The first protein discovered to translocate 
into the nucleus was the HIV-1 transcription-transactivating (Tat) protein, demonstrated 
by Frankel and Pabo in 1988, with the minimal sequence being isolated in 1997 [79]. 
Penetratin, a 16-residue CPP isolated from the Drosophila Antennapedia (ANTP) 
homeodomain, was discovered in 1994 [79]. Protein/peptide engineering has developed a 
combination of domains with different properties to generate chimeric CPPs. 
Subsequently, growing knowledge based on the identified properties of CPPs has led to 
the development of novel CPPs with completely designed sequences. Based on their 
physicochemical properties, CPPs may be classified as cationic peptides with positively 
charged surfaces, hydrophobic peptides with high hydrophobic amino acid content, or 
amphipathic peptides with both hydrophobic and hydrophilic fragments [73]. As 
summarized in Table 1, independent of CPP origin or classification, several algorithms 
have recently been built to allow for prediction of amino acid sequences that potentially 
have translocating properties [80-91].
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Intracellular delivery of various cargos is mediated by binding to CPPs either 
covalently or noncovalently [17, 72, 76]. CPPs can be directly attached to their cargo 
molecules through covalent linkage, termed covalent protein transduction (CPT). 
However, CPT involves relatively expensive and labor-intensive synthesis, and may not 
be suitable for the delivery of nucleic acids and nanoparticles. Noncovalent protein 
transduction (NPT) utilizes noncovalent association, such as electrostatic interactions and 
hydrophobic effects, between CPPs and cargo molecules. The major advantages of NPT 
over CPT are simplicity of preparation, cargo versatility, and low working 
concentrations, which possibly contribute to reduced toxicity. However, NPT may suffer 
from premature dissociation of cargos from CPPs and off-target effects within cells due 
to the relatively weak interacting forces between CPPs and cargos.
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Table 1. Predictors of cell-penetrating peptides.
Nam e W ebsite Reference
CPPsite 2.0 http://crdd.osdd.net/raghava/cppsite/ 1801
CPPpred http://bioware.ucd.ie/~com pass/biowareweb/Server pages/cpppred.php ML
KELM -CPPpred http://sairam .people.iitgn.ac.in/KELM -CPPpred.htm l [821
CellPPD http://crdd.osdd.net/raghava/cellppd/subm ission.php I83L
C2Pred http://lin-group.cn/server/C2Pred 1811
CPPred-RF http://server. m alab.cn/CPPred-RF/ ML
SkipCPP-Pred http://server.m alab.cn/SkipCPP-Pred/Index.htm l ML
M LCPP http://www.thegleelab.org/M LCPPExam ple.htm l ML
CPPred-FL http://server. m alab.cn/CPPred-FL/ M L
G-DipC N/A ML
StackCPPred https://github.com /Excelsior511/StackCPPred I9 0 1
TargetCPP N/A M L
N/A: not availab e
3.3.2. Mechanisms of CPP Action. Due to their inherent ability to cross plasma 
membranes, CPPs have been employed extensively to facilitate the transport of cargo 
molecules into cells. However, the detailed cellular uptake mechanism of CPPs is not
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well understood. Generally, it is accepted now that CPPs and CPP-cargo complexes are 
predominantly internalized into cells by two main pathways: endocytosis and direct 
translocation [17, 76, 77, 92]. However, the exact cellular uptake mechanism of CPPs and 
CPP-cargo complexes is determined by numerous factors, such as the amino acid 
sequences of CPPs (hydrophobicity and net charge), extracellular concentration of CPPs, 
cargo properties, cell type, and the assay temperature [92]. No matter what mechanism, 
the electrostatic interactions between the positively charged residues of CPPs and 
negatively charged glycosaminoglycans, especially heparan sulfate proteoglycans, of the 
membrane are the first crucial step for cellular uptake of CPPs and CPP-cargo complexes 
[92].
Endocytosis is a natural and energy-dependent process, occurring in almost all 
cells by direct interaction with the plasma membrane or by electrostatic interactions with 
cell surface proteoglycans [76, 92]. Endocytosis can be classified as phagocytosis (cell 
eating) or pinocytosis (cell drinking) [76]. Different types of pinocytosis include 
macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis, and 
clathrin- and caveolae-independent endocytosis [93]. The internalization mechanism for 
CPP-cargo complexes may involve a combination of specific pathways [76]. Moreover, 
several endocytic pathways can be used in parallel, or alternative pathways can 
compensate for the inhibition of specific pathways [17].
Direct translocation, also known as direct membrane penetration, is an energy- 
independent process where CPPs and CPP-cargo complexes directly penetrate through 
cellular membranes [76]. This direct translocation model involves a passive membrane 
diffusive or destabilization process that does not require binding to proteinaceous cell
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surface receptors. Direct physical interaction between the cationic residues of CPPs and 
the anionic phospholipids of the plasma membrane leads to direct membrane penetration 
[17]. Direct translocation usually completes in a short timescale, as little as 5 minutes. 
Energy-independent internalization of CPP-cargo complexes can be observed by 
incubating cells at low temperatures (4°C), since low temperature treatment seizes all 
energy-dependent movement across the cell membrane. CPP-cargo complexes that 
directly penetrate the membrane have similar uptake at 4 or 37°C [17]. So far, the 
mechanism of direct translocation can be explained by three main models: the inverted 
cell model, the pore formation model, and the carpet model [92].
3.3.3. Applications of CPPs in Clinical and Gene Therapies. Today, there is 
an urgent need to develop new therapeutic agents. Many conventional treatments are 
outdated and less desirable due to drug resistance, low selectivity, and poor solubility 
[74]. Therapeutic peptides are a promising and novel approach to treat many diseases, 
including cancer and genetic disorders. Therapeutic peptides have several advantages 
over proteins or antibodies, as they are easy to synthesize, have high target specificity as 
well as selectivity, and have low toxicity. Nevertheless, therapeutic peptides do have 
significant drawbacks related to their stability and short half-life [74].
In 1995, one of the earliest examples of a CPP used in gene therapy was 
demonstrated. The ANTP CPP was covalently linked to an antisense DNA of amyloid 
precursor protein (APP), which gave the antisense treatment direct access to the cell 
cytosol and nucleus [78, 94]. Internalized antisense oligonucleotides mediated by ANTP 
decreased APP protein expression, resulting in the inhibition of neurite outgrowth [94]. 
Later, in 1997 the first noncovalent delivery of oligonucleotides was demonstrated using
MPG, a 27-residue chimeric CPP [79, 95]. Kardani et al. demonstrated reporter gene 
expression in 25 to 55% of mammalian cells transfected with CPPs [96]. Accordingly, 
numerous CPPs have been reported to assemble antisense oligonucleotides, small 
interfering RNA (siRNA), or plasmid DNA into CPP-cargo nanoparticles, possessing 
positive charges that allow them to interact with cellular membranes and to internalize 
into cells [73, 97, 98].
In vivo delivery of nucleic acids is a challenge that has to be solved before gene 
therapeutic applications can be translated into the clinics [99]. Preferably, the delivery 
should be applicable for systemic administration, because this has the potential to reach 
all corners of the body. Despite intensive research over the last 20 years, only a few gene 
therapeutic vectors have been approved for the use in clinics [100]. Many clinic studies 
have revealed safety issues along with inefficiency problems. In 2012, the first 
statistically significant clinical trial opened the door for clinical delivery of 
macromolecular therapeutics [101]. Subsequently, there were over 25 clinical trials 
performed predominantly using CPPs in 2015 [102], and many pre-clinical and clinical 
trials with CPP-derived therapeutics were conducted in 2017 [103].
In addition to positive or negative regulation of gene products, CPPs may be used 
for the delivery of genome editing tools [73, 98, 104, 105]. In fact, an innovative 
application of CPP-mediated delivery of the CRISPR-Cas9 system in genome editing was 
reported in 2014 [106]. Both covalent conjugation of Cas9-CPP by a thioether bond and 
noncovalent CPP/single-guide RNA (sgRNA) complexing led to efficient gene 
disruptions in several human cell types with low off-target incision effects. This study 
demonstrated CPP-enabled direct delivery of both recombinant Cas9 protein and sgRNA
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into cultured mammalian cells [98, 105]. However, the genome editing frequency of this 
Cas9-CPP and CPP/sgRNA treatment tended to be low (less than 15% after three rounds 
of treatment) [107].
Collectively, CPPs have long been regarded as promising therapeutic delivery 
vehicles, not only because of their high internalization ability but also their potential for 
modification [92]. As promising carriers, CPPs generally have several advantages, such 
as low cytotoxicity, ease of preparation, and a wide variety of cargo type compatibility 
[74, 92, 108]. However, there are still shortcomings for drug delivery in vivo, such as 
cell-free specificity, short duration of action, and lack of oral bioavailability [74, 92, 
108].
4. VIRAL METHODS
The goal of any virus is to infect and exploit host cells by injecting nucleic acids 
into their cytoplasm and taking over the host’s cellular machinery. The life-cycle of a 
virus makes them a particularly promising carrier for gene therapeutics. However, for 
safety reasons, viral and retroviral vectors have to be modified to reduce their 
immunogenicity and cytotoxicity. Modification usually involves deletion or truncation of 
viral genes necessary for viral replication. Currently, viruses used as vectors for nucleic 
acid delivery have recombinant, replication-defective genomes that have had therapeutic 
genes added into them. Often, helper vectors or viruses are used to package the 
replication-defective viruses that carry therapeutic genes, which reduces the chance for 
viruses to gain competency. In the below sections, applications, advantages, and
disadvantages of viral and retroviral vectors as carrier platforms are discussed. Viral 
delivery methods are diagramed in Figure 4.
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Figure 4. Viral methods of gene delivery. Viral vectors vary in particle size, genome size 
and type, transgene capacity, capsid geometry, and whether they have an envelope or not. 
Vectors enter either by endocytosis or through membrane fusion. Integration of delivered 
nucleic acids into the host genome is dependent on the virus type.
4.1. ADENOVIRUS (AV) VECTORS
Adenoviruses (AVs) were first isolated from human adenoid tissue in 1953 [109]. 
These viruses were the first viruses used for gene therapy in the 1990s and later they 
began to be tested in clinical trials [109]. In 1993, the first in vivo human gene therapy 
was performed in a cystic fibrosis patient using a recombinant AV vector [110, 111]. 
However, sufficient precautions were not taken with this early vector and later trials led 
to the death of Jesse Gelsinger in 1999 [14].
Adenoviruses are non-enveloped viruses with icosahedral capsids ranging from 
60 to 90 nm in size. They contain a linear, double-stranded DNA genome of 30 to 40 kb 
and enter host cells by clathrin-mediated endocytosis [112]. The genome of adenoviruses 
includes various transcriptional units, which can be categorized based on when they are 
transcribed [6]. The units are early genes (E1A, E1B, E2, E3, and E4), delayed early (IX 
and Iva2), major late (ML), and late genes used in post-translational processing (L1, L2, 
L3, L4, and L5) [6]. The E1 region and a portion of E3 region in the AV genome were 
eliminated in the first-generation of recombinant AVs in order to accommodate a 
transgene. In addition to the potential of gaining replication competency in packaging cell 
lines, recombinant AVs tend to elicit a powerful immune response and cytotoxicity. To 
alleviate these undesired outcomes, vectors were further modified in a second generation 
where the E2 and E4 regions, which are responsible for immune reactions, were deleted 
[113, 114]. This also allowed the transgene packaging capacity of the vectors to increase 
from 5 kb to 14 kb. Further manipulations to produce a third generation of AV vectors 
nearly depleted the entire AV genome while allowing it to accommodate up to 37 kb 
target genes for delivery [115]. Genome components crucial for viral DNA replication 
and packaging were retained [6]. The onset of expression can occur as early as 16 to 24 
hours after infection.
Adenoviral DNA cannot integrate into the genome and is unable to replicate 
during cell division, which imposes limitations for broader gene therapy; on the other 
hand, this eliminates the possibility of chromosomal rearrangements that could lead to 
potential tumor formation [116]. One group showed gene transduction efficiencies of 55 
to 93% after using 4 different adenoviral vectors to infect CD34+ cord blood cells in vitro
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[117]. Their highly efficient transduction of most tissue, high levels of protein 
expression, and transient gene expression make them attractive in gene transfer and 
therapy [118]. Including trials up to 2017, 20.5% of gene therapy trials used adenoviral 
vectors [21].
4.2. ADENO-ASSOCIATED VIRUS (AAV) VECTORS
Adeno-associated virus (AAV) was discovered in the mid-1960s when scientists 
were studying adenovirus and later identified AAVs in human tissues [119, 120]. A 
journey of 20 years to understand AAV biology eventually yielded the first AAV vector 
used for in vitro gene delivery in 1984. The first human test of AAV vectors was to treat 
a patient with cystic fibrosis in 1995 [121]. In 2012, the European Medicine Agency 
approved the first AAV vector-based gene therapy drug to treat lipoprotein lipase 
deficiency.
Adeno-associated viruses are non-enveloped, single-stranded DNA viruses with 
4.7 kb genomes that are encapsulated in icosahedral capsids 18 to 25 nm in diameter. 
Wild-type AAVs require a helper virus to complete their life cycle. The non-pathogenic 
nature and the ability to package various transgenes make AAVs an ideal vehicle for gene 
therapy [121, 122]. AAVs are internalized by endocytosis mediated by clathrin [6]. The 
genome of the most commonly used serotype, AAV2, contains genes that encode 
regulatory Rep proteins and structural Cap proteins. The former carry out genome 
excision from the host chromosome, replication, packaging, and integration whereas the 
latter produce capsid proteins. Inverted terminal repeats flanking the genome possess 
regulatory cis-acting sequences needed for the virus to complete its life cycle and for
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integration into the host genome. In making AAV vectors, Rep and Cap were removed 
from AAV DNA to make room for therapeutic genes. Required proteins are provided to 
the virus by helper vectors during vector production [123]. An example of vector 
production in HEK293 cells would involve the functions of Rep and Cap being supplied 
in a separate helper vector, with an additional helper vector containing the E4, E2a, and 
VA regions required for replication [123].
The primary disadvantages of AAV vectors are that delivery is limited to smaller 
sized genes of interest (less than 5.0 kb of DNA), a slower onset of expression (2 to 7 
days for in vitro and 3 to 21 days for in vivo), and relatively low levels of protein 
expression that leads to a necessity to re-administration AAV vectors. Another significant 
drawback of AAVs is that they often trigger immune responses. For instance, neutralizing 
antibodies lead to rapid clearance of AAVs from the circulatory system by opsonizing 
viral particles and thus facilitate uptake by phagocytic cells. To overcome this issue, 
certain strategies have been employed that include re-engineering AAV vectors, use of 
capsid decoys, changing the route of administration, plasmapheresis, disruption of B cell 
activation and reduction of the number of activated B cells, and targeting T cell 
activation. Each method has disease-dependent pros and cons [124].
Currently more than nine different serotypes of AAV vectors have been used in 
clinical trials. The infectivity of AAVs in different cell types can be increased by utilizing 
different serotypes. Liver, eye, heart, muscle, brain, and bone have been targeted for 
therapy. Most of these trials are in phase I and/or II, while only a few have entered phase
III. Around 7.9% of gene therapy clinical trials used AAV vectors up until 2017 [21]. The 
transduction of AAV vectors is rate-limited by the necessity for AAV single-stranded
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DNA to be converted to double-stranded DNA before transcription [121]. It was 
demonstrated that an AAV alone was only able to transduce approximately 5 to 20% of 
HEK293T or HepG2 cells [125]. However, this has been improved by using methods, 
such as self-complementary vectors, to overcome the rate-limiting step [126].
4.3. RETROVIRAL VECTORS
Retroviruses are enveloped viruses with two identical copies of single-stranded 
RNA that range in length from 7 to 10 kb [127-130]. The entire viral particle is about 100 
to 200 nm. Retroviruses are classified as simple retroviruses or complex retroviruses 
according to their genomic organization and biological features. Gamma-retroviruses and 
lentiviruses are representative simple retroviruses and complex retroviruses, respectively. 
All retroviruses enter into cells either by receptor-mediated endocytosis or membrane 
fusion [131, 132]. The unique features of retroviruses lie in their capability to reverse 
transcribe their RNA into complementary DNA (cDNA) via reverse transcriptase activity 
and to integrate the cDNA into the host genome via integrase activity. The integration 
allows for hijacking the host’s replication machinery for viral reproduction for further 
infection. In the below sections, two major types of retroviral vectors for gene therapy are 
discussed.
4.3.1. Gamma-Retroviral Vectors. Gamma-retrovirus possesses a simple 
genome structure. The gag gene encodes structural proteins and proteins pertaining to the 
budding process. The pol gene codes for a protease, a reverse transcriptase, and an 
integrase. The protease cleaves the gag polyprotein. The reverse transcriptase is needed 
for the generation of viral cDNA from viral RNA and the integrase aids integration of
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viral cDNA into the host cell genome. All regulatory elements involved in viral RNA 
processing lie in the long terminal repeat (LTR) regions of viral genome.
The most commonly used retroviral vector for gene therapy was derived from 
murine leukemia virus (MLV), which is a simple gamma-retrovirus [132] with a nearly 
spherical capsid [133]. The first ex vivo gene therapy trial was approved in 1990 by the 
FDA. This trial treated the white blood cells of two young adenosine deaminase 
deficiency patients with a modified MLV vector carrying a normal gene [134, 135]. The 
efficiency of the therapy was debated [134]. Throughout decades, safety considerations 
have directed the evolution and development of the MLV vector system. The goal of 
manipulating vector arrangement was to remove its replication competence. The most 
advanced third generational gamma-retroviral vectors utilize a split-genome approach 
comprised of three plasmids. The main retroviral vector contains the LTR, a primer 
binding site for reverse transcription, and the packaging signal, as well as the transgene 
which can be up to 8 kb long. The structural and enzymatic retroviral genes are located in 
two helper plasmids. The gag, pol, and env genes in the helper plasmids do not contain 
retroviral elements pertaining to packaging, thereby reducing the probability of 
recombination [132]. To further improve safety, self-inactivating (SIN) vectors were 
developed by making the 3’-LTR nonfunctional. Even with so many modifications, once 
genes are delivered to cells, insertional mutagenesis, enhancer interaction, or premature 
termination may occur, which can lead to severe side effects.
Gamma-retroviral vectors have been used to transfer genes to hematopoietic stem 
cells to correct blood-related genetic disorders and skin diseases, such as Wiskott-Aldrich 
Syndrome, SCID-X1, SCID-ADA, epidermolysis bullosa, and melanoma [11, 136-143].
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In an ex vivo trial using gamma-retroviruses to treat SCID-X1, Gaspar et al. 
demonstrated an approximate 68% transfection efficiency in CD34+ bone-marrow stem 
cells [140]. Currently, approximately 17.9% of gene therapy clinical trials use retroviral 
vectors [21]. However, treating patients with integrating viruses is risky as integration has 
been associated with mutagenesis and oncogenesis when normal genes are disrupted or 
onco-genes are activated. For instance, in one trial of nine SCID-X1 patients, four 
patients treated with gamma-retroviral vectors developed T cell leukemia after gene 
therapy [136, 139].
4.3.2. Lentiviral (LV) Vectors. Lentivirus (LV) vectors are derived from HIV-1. 
They were first used in clinical trials in 2003 to deliver an antisense sequence for the 
HIV-1 envelope gene to CD4+ cells ex vivo [144]. In addition to gag, pol, and env found 
in gamma-retroviruses, the HIV-1 virus contains two regulatory genes, tat and rev, that 
are essential for replication. Tat and rev regulate trans-activation of gene expression and 
nuclear export of mRNAs. Importantly, HIV-1 contains four accessory genes that encode 
critical virulence factors for virus transmission enhancement. The lentiviral capsid is 
cone-shaped, rather than spherical [133]. In order for HIV-1 to be used safely in gene 
therapy, significant modifications to its genome were carried out [145].
The first generation of lentiviral vectors consisted of a major portion of the HIV 
genome, including retention of the gag and pol genes. The envelope protein (env) was 
supplied by another virus called VSV-G, which broadened the range of mammalian cells 
that could be transduced. The second generation took out accessory virulence genes, such 
as vif, vpr, vpu, and nef, without compromising transduction efficiency. The third 
generation of lentiviral vector systems underwent significant genome rearrangement and
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contained four plasmids: a vector plasmid, two packaging plasmids (containing gag, pol, 
and rev separately), and one envelope plasmid (containing env from VSV-G). The split- 
genome approach was intended to maximize the segregation of cis- and trans-acting 
functions and to minimize the possibility of homologous recombination events in order to 
reduce the generation of replication-competent lentiviruses. The removal of all accessory 
genes in the vector plasmid achieved a higher safety level. The gene tat was replaced by a 
modified LTR with a constitutively active promoter sequence [146]. The LTR sequence 
was further modified to become self-inactivating (i.e., SIN 5’ and 3’ LTR) [131]. To 
enhance viral titers and transgene expression, central polypurine tract/central termination 
sequence (cPPT/CTS), an enhanced promoter, and a woodchuck hepatitis virus 
posttranscriptional regulatory element were included [123]. Similar to gamma-retroviral 
vectors, lentiviral vectors can deliver transgenes up to 8 kb in length [67].
The most distinctive advantage of LVs over other retroviral vectors is their ability 
to penetrate the nuclear envelope of non-dividing cells. This extraordinary characteristic 
allows lentiviral vectors to be used in neurons and other non-dividing cells in adult 
organisms [147]. In addition, lentiviral gene therapies have been used in vascular 
transplantation, chronic granulomatous diseases, prostate cancer, heamophillia A, 
rheumatoid arthritis, and diabetes mellitus [148-151]. In the past decade, the clinical use 
of LVs has gained significant traction in gene transfer into CD34+ hematopoietic stem 
cells (HSC) to treat a variety of genetic disorders, such as P-thalassemia, X-linked 
adrenoleukodystrophy, metachromatic leukodystrophy, and Wiskott-Aldrich Syndrome 
[10, 12, 13, 152, 153]. Ex vivo transduction of HSCs with a lentiviral vector to treat 
Wiskott-Aldrich Syndrome resulted in 88 to 100% gene transfer efficiencies in CD34+
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bone-marrow stem cells [10]. Approximately 7.3% of gene therapy clinical trials utilized 
lentiviral vectors up until 2017 [21].
5. GENOME EDITING
Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), and CRISPR systems recognize and cut DNA sequences and have been 
utilized for genome editing [1]. ZFNs, TALENs, and CRISPR systems function through a 
DNA-targeting domain and a non-specific nuclease domain, resulting in a double strand 
break (DSB) in the DNA at the target site. The DNA-targeting domain is unique to each 
system, but the cleavage and cellular repair of a break are similar.
After a double-stranded DNA break in a eukaryotic cell, the conserved homology- 
directed repair (HDR) or non-homologous end joining (NHEJ) pathways are used to 
repair the gap [154]. NHEJ repairs the DNA break by quickly ligating the strands; 
however, it is not accurate and frequently results in short insertions and/or deletions that 
generate loss-of-function mutations [154, 155]. This may be desirable if gene inactivation 
is the goal. NHEJ-mediated repair is dominant in cells in the G0 and G1 phases of the cell 
cycle [156]. In HDR, a strand of template DNA similar to the breakage site is used to 
repair the gene [154, 155]. Homologous DNA with corrected bases can be delivered with 
gene editing tools and used as a template to fix the gene or add in a new gene [154]. 
However, HDR is restricted to cells in the S and G2 phases of the cell cycle [156].
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Figure 5. Genome editing techniques. All methods function by causing double strand 
breaks in DNA at targeted sequences. Cells repair the damage through non-homologous 
end joining (NHEJ) or homology-directed repair (HDR). ZFNs and TALENs share the 
same endonuclease (FokI) to induce breaks but target sequences using either zinc finger 
(ZF) or transcription activator-like effector (TALE) protein subunits. CRISPR uses a Cas 
endonuclease and targets DNA with a single-guide RNA (sgRNA).
ZFNs and TALENs rely on proteins to specifically interact with DNA sequences 
and CRISPR systems use a RNA guide sequence [1, 157]. The use of RNA for targeting 
makes CRISPR-Cas9 systems easier to manipulate than ZFNs and TALENs as proteins 
must be engineered to bind new DNA sequences [157]. The rate of mutations induced by 
these systems varies, with ZFNs having low success rates ranging from 0 to 19% [158], 
TALENs ranging from about 2 to 56% [159], and CRISPR ranging from approximately 2 
to 80% [160]. CRISPR systems have emerged as the front-runner for genome editing due 
to higher success rates and simpler target alteration. However, in order to function, 
editing tools need to be delivered into cells [1]. Some of the above methods may be used,
but the safety and efficiency of these delivery systems still need to be considered.
Genome editing techniques are diagramed in Figure 5.
5.1. ZINC FINGER NUCLEASES (ZFNs)
Zinc finger nucleases (ZFNs) are site-specific endonucleases that induce double­
strand breaks in DNA [154]. They can be designed to target specific DNA sequences. 
ZFNs are zinc finger proteins, a type of eukaryotic transcription factor, linked to a FokI 
restriction enzyme nuclease domain, which is of bacterial origin [154, 161]. The zinc 
finger proteins provide specificity and the restriction enzyme enables the DNA to be cut 
[154]. Both segments can be modified individually for optimization and then joined. The 
combination of modular DNA sequence-specific proteins and the non-specific FokI 
nuclease domain was first developed in 1996 [157, 161], with initial applications 
demonstrated in mammalian cells and Drosophila [157]. ZFNs have been used to target 
gene sequences in CHO cells, human cells, Drosophila, zebrafish, tobacco plants, and 
nematodes [155].
Zinc fingers proteins are very diverse in nature and very few residues are 
conserved between them [162]. They often contain cysteine and histidine amino acids 
that provide essential interactions with a zinc ion, which stabilizes the folding of the 
protein [162, 163]. Zinc fingers containing two cysteines and two histidines (Cys2-His2) 
play roles in protein interactions with DNA, RNA, and other proteins [162] and many are 
transcription factors [163]. Zinc fingers used in ZFNs are of this type [154]. Cys2-His2 
zinc fingers often fold into a two-stranded antiparallel P-sheet and an a-helix, which bind 
around the zinc ion [162]. Generally, the cys residues are located at one end of one P-
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sheet and the his residues are in the a-helix C-terminal area, with variable spacing. Loss 
of function results from alteration of the either the cys or his residues, indicating their 
essential role. The fingers in a protein are linked with a spacer sequence that influences 
“the spacing of the fingers along the DNA site” and is important for DNA binding 
affinity [162]. When binding DNA, the protein wraps around the helix, with each a-helix 
of individual fingers interacting with the major groove. The residues along the surface of 
the finger’s a-helix seem to be responsible for base-specific interactions [162, 163]. 
Finger proteins also interact with the phosphate backbone of the same DNA strand base 
interactions are made with, further securing the protein [162].
The FokI domain is only functional as a dimer, formed by two separate ZFNs 
binding DNA and orienting their nuclease monomers into the proper orientation [154]. 
Each finger binds specifically to about 3 DNA base pairs, with early studies incorporating 
3 fingers and more recent ones using up to 6 per monomer, allowing 18 to 36 base pairs 
to be recognized with the dimer [154]. Libraries of zinc fingers have been assembled that 
specifically bind combinations of the three base pair sequence, allowing zinc fingers to be 
selected and bound sequentially in order to target the desired DNA sequence [164]. Using 
different combinations of fingers in the set of dimers allows for longer sequences to be 
targeted [154]. However, designing ZFNs with sequence-specificity can be difficult 
because combining natural and synthetic fingers modularly can result in unforeseen 
interactions between other fingers and DNA bases [154]. Engineering new synthetic 
fingers can be complex [1].
Off-targeting is a major concern with ZFNs. Fingers may bind to and cut similar 
sequences in the genome, other than the one intended [154]. If two different ZFNs are
paired together to target a sequence, off-targeting may also occur because homodimers 
can form. However, this particular issue has been resolved by developing ZFNs that only 
function as heterodimers [154, 165]. ZFNs can also be toxic, likely due to off-targeting, 
with only 20 to 60% of 293T cells surviving transfection with ZFN plasmids [166]. ZFNs 
may not efficiently break a sequence if chromatin structure is too dense, due to the 
necessity of the protein fingers wrapping around the DNA helix [154]. ZFNs have not 
been used extensively since their development because of the complexity in designing 
fingers to target new sequences and the difficulty in validating binding [157].
5.2. TRANSCRIPTION ACTIVACTOR-LIKE EFFECTOR NUCLEASES 
(TALENS)
Similar to ZFNs, transcription activator-like effector nucleases (TALENs) cause 
double strand breaks in DNA using a FokI nuclease domain joined with a DNA-targeting 
domain [167, 168]. TALENs were created in 2010 [169, 170], originally with FokI 
because the targeting domain was inserted into the same plasmid used to create ZFNs 
[171].
The DNA targeting domain of TALENs, transcription activator-like effectors 
(TALEs), were discovered in Xanthomonas, a genus of bacterial plant pathogens [171]. 
TALEs mimic eukaryotic transcription factors and are secreted by the bacteria to weaken 
plant cells, making them more vulnerable to attack after their gene transcription is 
altered. TALEs can be engineered for DNA binding specificity [168]. Since their 
discovery, TALENs have been applied in a variety of cells and organisms, including 
yeast, Drosophila, human cell lines, zebrafish, frogs, rice, and roundworms [168].
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The potential of TALEs for DNA targeting is greater than zinc fingers. Individual 
TALE subunits can be modularly combined in order to produce a sequence-specific 
binding protein [164]. TALE subunits are composed of a highly conserved amino acid 
sequence ranging from 33 to 35 residues long and were discovered because of their 
repeating sequence [168]. TALE repeats in the natural protein are flanked by amino- and 
carboxy-domains, which are also incorporated into TALENs. Each subunit in a TALE 
array binds one nucleotide. Hypervariable residues at positions 12 and 13 are responsible 
for base-specificity [171]. Multiple of these diresidues can bind the same base with 
varying efficiency. The most common diresidues used in research to bind the DNA bases 
A, T, G, and C are the amino acid pairs NI, NG, NN, and HD, respectively; however, NN 
has also been shown to bind A so NH and NK have been implemented to decrease off- 
targeting [171]. The conserved amino acids in each monomer fold into a-helices on either 
side of the hypervariable residues, forming a v-shape [168]. These v-shaped subunits fit 
into the DNA major-groove so that their diresidues make contact with the bases and 
together wrap around the DNA to form a superhelix [168].
Due to the use of FokI, TALENs also function in pairs [171]. Targeting domains 
are designed to bind to opposite DNA strands with 12 to 25 base pair spacing between the 
binding points. TALENs are often created to target 18 or more base pair sequences, 
though specificity may decrease with longer chains [167]. TALENs have lower toxicity 
and higher specificity than ZFNs [165]. Production and validation of TALENs is also 
easier [157]. However, off-targeting may still be a concern and they are much larger than 
ZFNs, making them more difficult to deliver to cells as many delivery methods have 
limits to cargo size [165]. Although, off-targeting seems to be less when TALENs are
used to target the same genes as ZFNs [167]. Each pair of TALENs still must be 
engineered when a new DNA sequence is to be targeted [169], which may have 
contributed to their limited application [157]. Regular use of TALENs may have also 
been hampered by the discovery of CRISPR-Cas9 shortly after they were developed.
5.3. CRISPR-CAS SYSTEMS
5.3.1. Development History. The CRISPR-Cas system was derived from an 
adaptive immune system of bacterial defense against foreign invaders, such as viruses, 
phages, and certain plasmids. In 1987, clusters of short palindromic DNA repeats 
separated by hypervariable spacer sequences were discovered in Escherichia coli [172]. It 
was revealed that the bacteria captured DNA segments from invading viruses or foreign 
DNA, and used them to create DNA repeats, termed clustered regularly interspaced short 
palindromic repeats (CRISPR) in 2002 [173]. These CRISPR allow the bacteria to retain 
a history of previous viral infections or transformed DNA in the bacterial genome. When 
the viruses or closely related ones attack again, the bacteria produce RNA segments 
transcribed from these CRISPR to target the invasive genetic material, similar to current 
uses of iRNA. CRISPR-associated (Cas) genes are usually located adjacent to each 
CRISPR locus and code for a variety of polymerases, nucleases (both DNA and RNA), 
helicases, and RNA-binding proteins. The bacteria use Cas9 or a similar enzyme to cut 
foreign DNA apart, which disables the viruses or destroys other harmful DNA.
In 2012, two research teams first developed the CRISPR-Cas9 system for genome 
editing based on the bacterial defense system [174-177]. As summarized in Table 2, the 
original developers have launched their own biotechnology companies. They shared the
41
2016 Tang Prize in Biopharmaceutical Science for their work in "the development of 
CRISPR/Cas9 as a breakthrough genome editing platform that promises to revolutionize 
biomedical research and disease treatment" [178]. They were also winners of the Canada 
Gairdner International Award in 2016. This genome editing approach has inarguably 
revolutionized the field of molecular biology and medical research, and has had a 
profound and rapid impact on the development of more effective strategies to conquer 
human genetic diseases and cancers. In terms of experimental practice, the CRISPR-Cas 
system is characterized by its simplicity to use, high success rate, and easiness in design, 
construction, as well as delivery [156]. Additionally, targeted mutations in multiple genes 
(also known as multiplex genome engineering) are possible with the CRISPR-Cas 
system. Thus, these features make the innovative CRISPR-Cas system an extremely 
valuable tool for the evaluation of investigational gene therapies. Ultimately,
Emmanuelle Charpentier and Jennifer Doudna won the 2020 Nobel Prize in Chemistry 
“for the development of a method for genome editing”.
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Table 2. Three original developers of the CRISPR-Cas9 system.




U niversity o f 
California, Berkeley, 
USA
U m ea University, 
Sweden
M assachusetts Institute 
o f  Technology, USA
Discovery
The use o f CRISPR- 
Cas9 system  to edit 
DNA
The use o f  CRISPR- 
Cas9 system  to edit 
DNA
The application o f 
CRISPR-Cas9 in  
m am m alian cells
Company founder
Caribou Biosciences, 




Editas M edicine, Inc.
Reference [176] [176] [177]
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5.3.2. Mechanism of CRISPR-Cas Action. The CRISPR/Cas system is a 
ribonucleoprotein complex and comprises two key components: a chimeric single-guide 
RNA (sgRNA) and a DNA endonuclease Cas protein for genome editing [105, 179]. 
Together, an appropriate sgRNA carries a Cas nuclease to target a specific genomic 
sequence. The detailed mechanism of CRISPR-Cas system comprises three phases, which 
are adaptation of spacer sequences, expression and mutation, and interference [180]. As 
of 2018, CRISPR-Cas systems are classified into three main types of Cas variants (and a 
dozen subtypes) have been developed and differ in their mechanisms of action [175,
179].
The first Cas system is the wild-type Cas9 protein from the type II CRISPR 
system of Streptococcus pryogenes, and is commonly used as a genome editing tool 
[176]. The original activity of this Cas9 protein cleaves DNA at specific sites, resulting in 
the creation of double strand breaks (DSBs). DSBs are then subjected to the error-prone 
repair by NHEJ or HDR [156]. The efficiency of CRISPR-induced HDR may be very 
low in vivo due to HDR being limited to S and G2 phase cells. The second Cas9 variant 
is Cas9D10A (a.k.a., nickase) [181], a mutant form of the Cas9 protein which cleaves 
only one DNA strand or modifies only one specific nucleotide [175, 179]. This activates 
the high-fidelity HDR pathway and downregulates NHEJ-mediated repair. The third Cas9 
version is dCas9 (dead Cas9, nuclease-deficient Cas9, or CRISPR interference; i.e., 
CRISPRi) [182], in which certain mutations were introduced to inactivate the protein’s 
cleavage activity but retain the DNA-binding activity. This dCas9 is a DNA complexing 
protein that can specifically interfere with transcription and modulate gene expression. It 
shall be remarked that the number and diversity of CRISPR-Cas systems are continuously
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expanding. Recently, a new evolutionary classification has been introduced to include 2 
classes, 6 types, and 33 subtypes [183]. The class 1 systems include multiple Cas proteins 
that form a CRISPR RNA-binding complex. By contrast, class 2 systems have a single, 
multidomain CRISPR RNA-binding protein, such as Cas9 in type II systems.
Several methods have also been developed related to CRISPR-Cas systems. Prime 
editing is a genome editing technique that produced higher precision and a wider 
selection of applications, potentially enabling researchers to correct up to 89% of known 
genetic variants [184]. This versatile and precise genome editing method uses a 
catalytically impaired Cas9 fused to an engineered reverse transcriptase and a prime 
editing guide RNA (pegRNA) that both specify the target site and encode the desired 
edit. Anti-CRISPRs (Acrs) are small proteins that have been identified to inhibit the 
RNA-guided DNA targeting activity of CRISPR-Cas proteins [185]. Three inhibitors, 
AcrIIA13, AcrIIA14, and AcrIIA15, were found to block CRISPR-Cas-mediated genome 
editing in human embryonic kidney cells. These inhibitors share a conserved N-terminal 
sequence that is required in DNA cleavage inhibition. Notably, a new base editor (BE) 
was developed by fusing dCas9 and cytidine deaminase that enabled the direct, 
irreversible conversion of one target DNA base into another in a programmable manner, 
without DSBs [186]. Instead of possible disruption of the entire genome, this BE creates 
point mutations at a targeted genomic locus with an efficiency of up to 75% using a 
CRISPR framework. This tool is like using an eraser and pencil to fix just a single letter. 
Another new CasRx ribonuclease effector was recently identified to exhibit favorable 
efficiency and specificity relative to RNA interference (RNAi) across diverse endogenous 
transcripts [187]. CasRx can be flexibly packaged into adeno-associated viruses to
manipulate alternative splicing, reducing pathological tau isoforms in a neuronal model 
of frontotemporal dementia.
5.3.3. Applications of CRISPR-Cas in Gene Therapy. In the post-CRISPR-Cas 
era, we have observed incredible increases in laboratory research from academic 
institutes and clinical applications from pharmaceutical companies. It was estimated that 
the genome editing market will be worth more than US$5 billion by 2021 [188].
Although the driving force of this rapid development was certainly CRISPR-Cas, both 
ZFNs and TALENs platforms reached the clinical stage before CRISPR-Cas. Many 
teams and companies have been working to translate CRISPR-Cas technologies into safe 
and effective human therapeutics [1, 188-192]. For instance, the Genome Project-write 
(GP-write) is an open, international research project, which focuses on whole genome 
engineering of human cell lines and other organisms of agricultural and public health 
significance [193]. In any case, genome editing must be accurate, efficient, and 
deliverable to the desired cells or tissues for safe and effective clinical use ex vivo and in 
vivo [194]. Currently, there are 10 clinical CRISPR studies under either recruiting or not 
yet recruiting status according to ClinicalTrials.gov [195]. In 2020, there were 19 
ongoing clinical trials using CRISPR-based gene editing [196]. However, none of these 
proposed clinical trials has been officially approved as new drugs by the US FDA. [190].
Since the discovery of the CRISPR-Cas system in 2012, the progress toward 
human trials has been slow [197]. For example, US FDA halted the proposed trial of 
CTX001 to use the CRISPR-Cas system for a single genetic change in patients with 
sickle cell disease. The status of the European trial using the same treatment in patients 
with beta-thalassemia was unaffected by this US FDA decision, and was still planned to
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be initiated later in 2018. In 2015, it was reported that the first CRISPR-Cas human 
clinical trial took place in China [190, 198]. There were 86 patients with various cancers 
that participated in these clinical CRISPR-Cas trials from 2015 to 2017. At least 15 
patients died during the trials, although the directors of clinical research claimed they 
died from their own cancers. One of the clinical trial directors from Hangzhou Cancer 
Hospital revealed that the cure rate of an ex vivo clinical CRISPR-Cas trial after 11 
months was approximately 40% from 21 patients with esophageal cancer [199].
However, no official or complete results from Chinese CRISPR-Cas human clinical trials 
have been reported to date. In November 2018, a Chinese biophysics researcher, He 
Jiankui, sent shockwaves across the world by claiming that he had utilized CRISPR 
technology to edit the genomes of two twin babies, Lulu and Nana [200]. His team 
attempted to introduce a mutation into their CCR5 genes, a gene encoding the T cell 
receptor that HIV viruses bind to, in order to prevent HIV infection. However, the 
ethically controversial announcement lead to his dismissal from the Southern University 
of Science and Technology in Shenzhen, China. He was also fined three million yuan and 
imprisoned for three years by the Chinese People’s Court in 2019.
The ongoing global pandemic of coronavirus disease 2019 (COVID-19), caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most 
devastating viral outbreaks in the past 100 years [201]. A rapid (less than 40 minute), 
easy-to-implement, and accurate CRISPR-Cas12-based diagnostic assay was developed 
for detecting SARS-CoV-2 from RNA extracts of respiratory swabs [202]. This DNA 
endonuclease-targeted CRISPR trans reporter (DETECTR) assay provides a visual and 
faster alternative to general assays. Additionally, a CRISPR-Cas13-based antiviral
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strategy was recently developed to target conserved sequences of coronaviruses and 
influenza A virus [203]. This strategy was named prophylactic antiviral CRISPR in 
human cells (PAC-MAN) and effectively degrades RNA from SARS-CoV-2 and 
influenza A virus in human lung epithelial cells. Bioinformatic analysis showed that a 
group of only six CRISPR RNAs can target more than 90% of all coronaviruses.
5.3.4. Concerns of CRISPR-Cas in Gene Therapy. Serious safety concerns 
about the use of CRISPR-Cas have been raised after the development of therapeutic 
genome editing applications [204]. CRISPR-Cas technology has enabled efficient 
genome editing and modifications in several model organisms, and has successfully been 
applied in biomedicine and biomedical engineering [205]. Much attention has also 
focused on the development of potential CRISPR-Cas therapies to cure complex heritable 
diseases in humans [206]. However, major challenges related to the effectiveness, 
specificity, and safety of the CRISPR-Cas system remain. Notably, safety guidelines for 
preclinical trial studies and ethical issues concerning genome editing and genomic 
analysis at the population level remain unsettled.
6. CONCLUSIONS
Gene therapy has evolved and improved over the past five decades. Methods 
started from non-specific and non-targeting and have become specific and precise with 
the ability to target genes that need to be corrected to eliminate disease. Correction can be 
an addition or a simple edit to a small stretch of a gene. Genetic delivery has been 
achieved at the cellular level and organismal level. CRISPR systems have gathered the
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main attention of gene therapy research due the system being viewed as an accurate and 
efficient technique with the potential to challenge all diseases. Gene delivery and genome 
editing will continue to develop in the twenty-first century, with advances in delivery 
efficiency and targeting specificity, though progress may be gradual due to necessary 
safety precautions. We have learned from past mistakes, where safety was not fully 
considered, and have faced morbidity and mortality among patients. Certain methods are 
likely to become more effective and safer for disease management, but other methods 
will still remain competitive due to ease of preparation and use, low cost, simplicity, and 
will still contribution to fundamental scientific endeavors in cell and molecular biology. 
As these techniques continue to develop, more applications will arise, treatments will be 
further tailored to individuals, and diseases with more complex genotypes will be able to 
be treated. As genome therapy becomes safer and highly efficient, we will be faced with 
more cases of edited humans and must question the line between disease treatment and 
playing god with our genetic code.
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ABSTRACT
Breast cancer affects the lives of millions of women around the world each year. 
Triple negative breast cancers (TNBCs) lack therapy methods with few side-effects. Less 
harsh treatment options are necessary to improve the overall outcome for cancer patients. 
DNA origami is a promising nanocarrier system. However, the uptake mechanism of this 
carrier is not well understood. In this study, we describe the killing efficiency of a model 
DOX-loaded DNA triangle origami (DOX-DNA-T) using viability reduction and 
apoptosis induction in two TNBC cell lines (MDA-MB-231 and MDA-MB-453). The 
internalization pathway of DOX-DNA-T was elucidated by inhibiting energy-dependent, 
clathrin-dependent, caveolin-dependent, and macropinocytosis pathways. The subcellular 
localization of DOX-DNA-T was determined by co-localization with organelle-specific 
dyes using a confocal microscope. DOX-DNA-T was able to increase the internalized 
DOX concentration and altered its subcellular localization. DOX-DNA-T delayed the 
killing of DOX, but modulated the toxicity between cell lines. The carrier facilitated 
DOX entry by clathrin- and caveolin-dependent endocytosis, as well as by
macropinocytosis. Understanding the cellular fate of DOX-DNA-T can help to better 
design DNA nanostructures as a drug delivery system.
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1. INTRODUCTION
In 2018, 18.1 million new cases of cancer were diagnosed worldwide [1]. Breast 
cancer contributed 11.6% of these cases and remains the second leading cause of all 
cancer related deaths, despite years of research and funding in the field [1]. Breast 
cancers are classified based on receptor upregulation and overexpression compared to 
normal tissue. The three most commonly upregulated and targeted receptors for treatment 
are the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal 
growth factor receptor (HER-2) [2]. However, these three receptors are absent in 15 to 
20% of breast cancers, which are referred to as triple negative breast cancer (TNBC) [2]. 
Consequently, approximately 367 thousand new cases of TNBC are diagnosed yearly, 
based on global cancer statistics. Because TNBCs lack the three common breast cancer 
receptors, they do not respond well to frequently used targeted therapies [2]. Recurrence 
and metastasis are also significantly higher in patients with TNBCs [3]. Metastasis is a 
large concern when treating cancer patients as metastasis is the cause of 90% of all 
cancer deaths [4]. Aggressiveness (i.e., fast formation and growth) and invasiveness 
make triple negative tumors difficult to remove surgically without causing harm to the 
surrounding healthy tissue [5]. All these factors result in worse prognosis for patients 
with TNBC compared to other breast cancers.
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There are few treatment options for patients with TNBCs and no FDA-approved 
targeted therapies against the cells of TNBC tumors [2]. Conventionally, TNBCs are 
treated by surgically removing the tumor mass in combination with radiation or 
chemotherapy [5-7]. During the course of treatment, a cancer patient is likely to receive 
anthracyclines (e.g., Doxorubicin, DOX), which efficiently kill cells that are actively 
replicating [8-10]. However, anthracyclines also destroy non-cancerous cells that quickly 
replicate. Even if they are not replicating, cells may be harmed as the metabolic reduction 
of anthracyclines results in hydroxyl free radicals [11]. Cardiomyocytes are particularly 
susceptible to damage by the free radicals produced by anthracyclines, resulting in side 
effects as severe as congestive heart failure [11]. Furthermore, resistance to DOX often 
develops in cancerous tissues treated with the drug [11], presenting major challenges for 
cancers with few treatment options or for recurring cancers. In order to decrease side 
effects of anticancer drugs like DOX, various carriers at the nanoscale are in development 
which increase drug delivery efficiency using the principle of enhanced permeability and 
retention. This principle is observed in tumors where vasculature is abnormally 
permeable and lymphatic drainage is low, leading to a buildup of compounds within the 
tumor [12]. Delivering drugs directly to tumors using nanocarriers can combat drug 
resistance by increasing retention time and can reduce overall toxicity in patients [13-15].
One promising nanoparticle being used for delivery is DNA. Using base pairing, a 
long single-strand of circular viral genome can be artificially folded into theoretically any 
desired shape with the help of short synthetic DNA strands (staple strands) to act as a 
carrier [13]. The resulting nanostructures, or DNA origami, have size-dependent drug­
loading capacity and drug release [15]. The amount of drug loaded is tunable based on
the length of the DNA strands and on DNA helix rotation [16, 17]. The use of DNA in 
nanostructures allows precise geometry to be designed and easy functionalization [13,
18]. Exact control of nanostructure geometry is desirable as it influences biodistribution, 
movement through fluids, and cellular internalization [19]. Because DNA nanostructures 
have been observed to possess a high affinity for and enhanced retention within tumor 
masses in vivo [18, 20], they have been evaluated to deliver anti-cancer drugs.
DNA nanostructures are an excellent carrier for anthracyclines, as the drugs 
readily intercalate into the DNA double helix and slowly dissociate [14, 15, 21]. In a 
previous in vitro study by Zeng et al., drug-loaded DNA nanostructures had higher 
accumulation and persistence in cancer cells compared to free DOX [15]. DNA 
nanostructures have shown the ability to passively target and localize in tumors in vivo 
[18, 20]. Despite the potential success of DNA nanostructure to deliver anti-cancer drugs 
to tumors, their exact cellular uptake mechanism and subcellular localization are still 
unknown, which are influential to drug delivery efficacy. In this study, we evaluated a 
model DOX-loaded DNA triangle origami (DOX-DNA-T) in two different TNBC cell 
lines: MDA-MB-231 and MDA-MB-453. We hypothesized that 1) DOX-DNA-T 
nanostructures would have more effective cellular uptake and killing efficiency in triple 
negative breast cancer cells than DOX alone, 2) the uptake mechanism of DOX-DNA-T 
would be energy dependent, and 3) DOX-DNA-T would localize within cellular 
organelles. This study provides insight to the cellular uptake mechanisms and the 
subcellular fate of DNA origami, with the potential to further improve the therapeutic 
efficacy of DNA origami as a carrier system.
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2. MATERIALS AND METHODS
2.1. DNA ORIGAMI PRODUCTION
Triangle origami were prepared from synthetic L-form M13mp18 phage single­
stranded genomes (Bayou Biolabs: Metairie, LA, USA) using techniques described in our 
previous publications [15]. Briefly, genomes and appropriately designed staple strands 
(Integrated DNA Technologies: Coralville, IA, USA) were mixed, incubated at 90°C, and 
allowed to anneal over a slow 12-hour cool down to room temperature. Desired shape 
was confirmed with atomic force microscopy (AFM). DOX (Fisher BioReagents: 
Pittsburgh, PA, USA) was loaded into the origami by incubating the folded structures 
with 1.2 mM of the drug for 18 hours at 37°C. Loading efficiency was calculated based 
on the concentration of free DOX in solution after pelleting the loaded origami and was 
in the range of 85 to 95%. The concentration was determined using a fluorescence 
spectrophotometer set to excite at 485 nm and record at 500 to 650 nm (Nanodrop 3300, 
ThermoFisher Scientific: Waltham, MA, USA), with the final concertation loaded being 
approximately 1 mM per 5 nM of origami. The stability of complexes was confirmed by 
incubation with different concentrations (2, 5, and 10%) of HyClone fetal clone serum 
(FCS, GE Healthcare Life Sciences: Marlborough, MA, USA), which is rich in proteases 
and DNases normally found in the blood. After incubation for various time periods, 
origami was run on 0.8% agarose gels containing ethidium bromide and imaged. Unless 
otherwise noted, the range of concentrations used to treat cells were 0, 0.0025, 0.005, 
0.01, 0.025, and 0.05 nM of naked origami; 0, 0.5, 1, 2, 5, and 10 pM of free DOX; or the 
equivalent concentrations of each component combined in DOX-DNA-T.
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2.2. CELL MAINTENANCE
MDA-MB-231 and MDA-MB-453 cell lines were purchased from the American 
Type Culture Collection (ATCC: Manassas, VA, USA) and were cultured in RPMI-1640 
medium supplemented with 5% HyClone FCS and 1% antibiotics (50 units/mL penicillin 
and 50 pg/mL streptomycin). Cells were maintained in tissue culture dishes in a 
humidified incubator at 37°C and 5% CO2. Both cell lines were harvested upon reaching 
80 to 90% confluency using trypsin for experiments or were split 1:2 to 1:4 every 2 to 4 
days. Cultures were replaced with cells from liquid nitrogen storage before exceeding 30 
passages. The pH of cultures was analyzed 24 and 48 hours after cells were established 
for 24 hours in order to determine if there were additional differences between the 
physiological conditions of the cells.
2.3. CELL VIABILITY
The viability of MDA-MB-231 and MDA-MB-453 cells was determined by 
seeding 50,000 cells for 48-hour and 100,000 cells for 24-hour experiments into 24-well 
cell culture plates with equal cell density per well. A lower starting density was used for 
longer incubations to prevent overcrowding in controls. Cells were allowed to adhere to 
the plates for 24 hours and then dosed with a concentration range of each component of 
the triangle origami. Viability was compared between naked origami, free DOX, and 
DOX-DNA-T. Viability was accessed using a standard sulforhodamine B (SRB) protein 
dye assay [22]. Briefly, after exposure for 24 or 48 hours, cells were fixed in 500 pL of 
10% trichloroacetic acid for 1 hour at 4°C. Cells were rinsed with distilled water three
times, excess water was removed by pipet, and plates were allowed to dry completely in a
refrigerator (at least overnight). Following drying, cells were stained with 500 gL of 
0.2% SRB in 1% acetic acid for 30 minutes on a rocker. Cells were then washed three 
times with 1% acetic acid, with each wash sitting for 20 minutes on the rocker. Excess 
acetic acid was removed from the wells and plates were air dried for 30 minutes. Tris- 
HCl (300 gL, 10 mM) was used to dissociate the dye from cellular proteins, 250 gL of 
the dye solution was transferred to a 96-well microplate, and color intensity was 
measured using a FLUOstar Omega microplate reader set to read absorbance at 510 nm 
(BMG Labtechnologies: Cary, NC, USA). Wells with no cultured cells that were stained 
and washed served as blanks. Cell viability was calculated as the sample well intensity as 
a percentage of the control well intensity, with blanks subtracted from both.
Cell viability, or culture growth, was also analyzed for MDA-MB-231 cells after 
incubation in media with different concentrations of FCS (2, 5, and 10%) to establish the 
appropriate testing conditions for the DNA origami. Cells were seeded at 80,000 cells per 
well in 24-well cell culture plates. Cells were grown until attached, approximately 4.5 
hours, and fixed to serve as a 0-time point. Other cells were grown for 24, 48, and 72 
hours after the 0-time point, fixed, and analyzed using the SRB assay. Cell viability was 
calculated as the sample well intensity as a percentage of the highest well intensity, with 
appropriate blanks subtracted from both.
2.4. APOPTOSIS
Annexin V-Alexa Fluor 647 is a dye that binds with high affinity to 
phosphatidylserine, a cell signaling molecule expressed on the cell surface during
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apoptosis [23]. Quantification of this molecule allows the portion of cells undergoing 
apoptosis to be determined.
For flow cytometry, MDA-MB-231 or MDA-MB-453 cells (300,000 cells per 
dish for 48-hour and 600,000 cells per dishfor 24-hour) were grown in 6 cm cell culture 
dishes for 24 hours before dosing with a concentration range of DOX or DOX-DNA-T 
for either 24 or 48 hours. After exposure, cells were washed with phosphate buffered 
saline (PBS), suspended from the plates using trypsin, and pelleted by centrifugation. The 
old media and PBS wash were collected and pelleted along with the trypsinized cells in 
order to prevent the loss of floating cells undergoing apoptosis. Cells were suspended in 
1 pL of Annexin V-Alexa Fluor 647 (50 pg/mL, BioLegend: San Diego, CA, USA) in 
100 pL of 1x Annexin V-binding buffer (BD Biosciences: San Jose, CA, USA), with a 
final dye concentration of 0.5 pg/mL. Cells were incubated with Annexin V-Alexa Fluor 
647 for 30 minutes at room temperature in the dark before analysis using a CytoFLEX 
flow cytometer (Beckman-Coulter: Brea, CA, USA) with the far-red filter set (ex: 638 
nm, em: 660/10 nm). For each experiment, 10,000 to 30,000 single cell events were 
captured. The population of cells undergoing apoptosis was determined using FCS 
Express 6 analysis software. Cells were considered apoptotic if they were positive for 
Annexin V staining.
For confocal microscopy, MDA-MB-231 or MDA-MB-453 cells (150,000 cells 
per dish for 48-hour and 300,000 cells per dish for 24-hour) were grown in 3.5 cm glass- 
bottomed cell culture dishes (MatTek: Ashland, MA, USA) for 24 hours before dosing 
with 10 pM of free DOX or an equivalent amount of DOX loaded into DNA-T. After 
exposure for 24 or 48 hours, old media was collected and cells were washed twice with
72
PBS. The first wash and old media were collected and centrifuged to harvest floating 
cells. The second wash was left on cells while centrifuging the media to prevent drying 
and was then discarded. Pelleted cells were suspended in 5 pL of Annexin V-Alexa Fluor 
647 (BioLegend, 50 pg/mL) in 500 pL of Annexin V-binding buffer, with a final dye 
concentration of 0.5 pg/mL. Dye solution and floating cells were then pipetted back into 
the sample dishes and evenly distributed by tilting the dish. Dishes were incubated for 30 
minutes at 37°C in the dark. Following incubation with Annexin V, cells were incubated 
with 1 mL of Hoechst 33342 (10 mg/mL stock, diluted 1:2000 in PBS) for 5 minutes at 
37°C in the dark. Cells were then imaged using a Nikon A1R HD25 confocal microscope 
comparisonusing a 40x Plan Fluor objective with 1.3 NA (Nikon Instruments: Melville, 
NY, USA). Green (ex: 488 nm, em: 500-550 nm), far-red (ex: 640 nm, em: 663-673 nm) 
and blue (ex: 405, em: 425-475 nm) filter sets were used to detect DOX, Annexin V, and 
Hoechst, respectively. Images were obtained using Elements software and a four channel 
High-Sensitivity/GaAsP PMT detector unit. Confocal images were analyzed in ImageJ 
(National Institutes of Health).
2.5. UPTAKE
Unless otherwise noted, the following setup was used for uptake experiments. 
MDA-MB-231 and MBA-MB-453 cells used for flow cytometry analysis were seeded 
into the wells of a 24-well plate at a density of 100,000 cells per well and allowed to 
grow for 48 hours before treatment. Drug concentration was selected to be 2 pM in 
uptake studies to limit cell death and ensure cells were healthy enough for internalization. 
DOX intensity was measured on a flow cytometer using the green filter set (ex: 488 nm,
73
em: 525/40 nm), as DOX itself is fluorescent with a peak excitation wavelength of 470 
nm and emission of 560 nm [24]. For each experiment, 10,000 to 30,000 single cell 
events were captured. For confocal microscopy, MDA-MB-231 and MBA-MB-453 cells 
were plated in 3.5 cm glass-bottom culture dishes at a density of 300,000 cells per dish 
and allowed to adhere for 48 hours. DOX intensity was also analyzed using a 488 nm 
laser line on the confocal. Confocal images were analyzed in ImageJ. All cells were 
washed twice before harvesting with trypsin or imaging. Pelleted cells were suspended in 
150 pL of PBS for flow cytometry. Cells were imaged in 1 mL of warm PBS. All 
inhibitor solutions were sterilized by using 0.2 pm syringe filters. Concentrations for 
inhibitors were the same as the ones used for our previous publication [25]. Live cell 
fluorescence was examined within 1 hour of washing or harvesting. Confocal images 
were analyzed in ImageJ.
2.5.1. Subcellular Localization. DOX-DNA-T were expected to be subcellularly 
localized in the lysosome, mitochondria, or nuclei. Using LysoTracker (Deep Red, 
Invitrogen: Carlsbad, CA, USA), MitoTracker (Deep Red, Invitrogen), and Hoechst 
33342, subcellular localization was revealed by co-localization with these specific 
markers. MDA-MB-231 and MBA-MB-453 cells were plated in 3.5 cm glass-bottom 
culture dishes and grown for 24 hours for microscopy. Cells were treated with 2 pM of 
DOX or DOX-DNA-T for 24 or 48 hours. The treated or untreated cells were incubated 
with specific markers following the instructions provided by the manufacturers. Briefly, 
LysoTracker and MitoTracker were prepared as 100x stock solutions and diluted in fresh 
media to 50 nM. Media was prewarmed and 2 mL of each solution was added to cells. 
Cells were incubated for 30 minutes at 37°C in the dark. Staining solution was discarded
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and samples were then incubated with 1 mL of warm Hoechst 33342 (10 mg/mL stock, 
diluted 1:2000 in PBS) for 5 minutes at 37°C in the dark. The cells were washed twice 
with warm PBS, 1 mL of warm PBS was added to each dish to keep the cells moist, and 
cells were then imaged using a confocal microscope.
2.5.2. Time-Dependent Uptake. The internalization of DOX and DOX-DNA-T 
was determined over the course of 0 to 4 hours and after 24 and 48 hours using flow 
cytometry. Cells were plated in 6-well culture plates at a density of 500,000 per well and 
allowed to grow for 48 hours before dosing with 2 pM of DOX or DOX-DNA-T. During 
0- to 4-hour experiments, cells were dosed at 0 minutes, 10 minutes, 30 minutes, 1 hour,
2 hours, and 4 hours before washing. For 24- and 48-hour experiments, cells were plated 
at 225,000 cells per well and 112,500 cells per well in 3.5 cm culture dishes, respectively, 
and allowed to grow for 48 hours before dosing. Surface area was accounted for in order 
to achieve the same cell density in different culture vessels. Select time points (1, 24, and 
48 hours) were chosen be imaged using a confocal microscope for visual comparison.
2.5.3. Energy Inhibition. Multiple forms of endocytosis, including clathrin- and 
caveolin-dependent endocytosis, as well as macropinocytosis, require energy for vesicle 
formation at the cell surface [26]. MDA-MB-231 and MBA-MB-453 cells were plated 
into a 24-well plate or glass-bottomed culture dishes for flow cytometry or microscopy, 
respectively. An inhibitor cocktail was prepared at 100x in water and diluted to 10x in 
PBS. Cells were pre-incubated with the metabolic inhibitor mixture (230 pM of sodium 
azide, 15 pM of sodium fluoride, and 2 pg/mL antimycin A) for 1 hour, followed by 
incubation with 2 pM of DOX or DOX-DNA-T for 1 hour. Cells were then imagined 
with a Nikon confocal microscope or harvested for analysis using a flow cytometer. DOX
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was expected to diffuse into cells [27-30], so further inhibition studies were carried out 
using only DOX-DNA-T.
2.5.4. Clathrin Inhibition. MDA-MB-231 and MBA-MB-453 cells were plated 
into a 24-well plate or glass-bottomed culture dishes for flow cytometry or microscopy, 
respectively. A 2x working solution of sucrose was prepared in water. A 1000x stock 
solution of chlorpromazine was prepared in water and was diluted to a 10x working 
solution in PBS. A 100x stock solution of monodansylcadaverine (MDC) was prepared in 
100% methanol and was diluted to a 10x working solution in PBS. Cells were pre­
incubated with 0.45 M sucrose, 10 pM chlorpromazine, or 25 pg/mL MDC for 30 
minutes at 37°C. Cells were treated with 2 pM of DOX-DNA-T for 1 hour and then 
imagined with a Nikon confocal microscope or harvested for analysis using a flow 
cytometer.
2.5.5. Caveolae Inhibition. To inhibit lipid raft-dependent caveolin endocytosis, 
filipin and nystatin were used to sequester cholesterol [31]. MDA-MB-231 and MBA- 
MB-453 cells were plated into a 24-well plate or glass-bottomed culture dishes for flow 
cytometry or microscopy, respectively. A 100x stock solution of filipin was prepare in 
1:4 DMSO:PBS and was diluted to a 10x working solution in PBS. A 100x stock solution 
of nystatin was prepare in 100% methanol and was diluted to a 10x working solution in 
PBS. Cells were pre-incubated with 3 pg/mL filipin or 20 pg/mL nystatin for 30 minutes 
before treatment with 2 pM of DOX-DNA-T for another 1 hour. Cell were then imagined 
with a Nikon confocal microscope or harvested for analysis using a flow cytometer.
2.5.6. Macropinocytosis Inhibition. MDA-MB-231 and MBA-MB-453 cells 
were plated into a 24-well plate or glass-bottomed culture dishes for flow cytometry or
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microscopy, respectively. Cells were pre-treated with EIPA (5-(N-ethyl-N-isopropyl)- 
amiloride (30 pM) or cytochalasin D (Cyt D, 1 pg/mL) for 30 minutes before treatment 
with 2 pM of DOX-DNA-T for another 1 hour. EIPA was prepared as 2 mg/mL stock 
solution in 100% methanol and diluted to 10x in PBS. Cyt D was prepared as 1 mg/mL 
stock solution in 100% ethanol and diluted to 10x in PBS. Cells were then imagined with 
a Nikon confocal microscope or harvested for analysis using a flow cytometer.
2.6. STATISTICAL ANALYSIS
Data are expressed as the mean ± standard deviation. One-way ANOVA followed 
by Tukey tests were used to compare the differences between all groups. A student’s t- 
test was used to compare differences between specific treatment groups and controls. All 
statistics were performed in MiniTab 19 and most graphs were produced in GraphPad 
Prism 4. Each in vitro experiment was carried out in at least three independent 
experiments. Statistical significance was set at p < 0.05.
3. RESULTS
3.1. DNA ORIGAMI PRODUCTION
DNA origami triangle folding and shape were confirmed using AFM (Figure 1A). 
DNA-T were approximately 50 nm across and their geometry was not altered by the 
intercalation of DOX. DNA-T showed higher stability in lower concentrations of FCS 
(Figure 1B), with the least band streaking observed in 2% FCS and the highest observed 
in 10% FCS. In 10% FCS, origami bands showed low streaking after initial mixing, but
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were destabilized relatively quickly. In 5% FCS, origami bands showed similar streaking 
from 0 to 8 hours, but began to show increased streaking after 12 and 24 hours. In 2%, 
origami appear to be stable after 16 hours of incubation.
(A)
DNA-T DNA-T + DOX
(B)
Oh 6h 12h 24h 
t  4
Oh lh  2h 4h 8h 12h 24h
m  y  Ld fcy < .
Oh 2h 4h 8h 16h
flfetfit mm. * *
Figure 1. DNA structure and stability confirmation using AFM and agarose gels. (A) 
AFM images of DNA origami triangles. Scale bar is 100 nm. (B) Agarose gel showing 
the stability of DNA-T incubated in RPMI-1640 cell culture medium (Left 10%, middle 
5%, and right 2% FCS) for the indicated time period.
3.2. CELL VIABILITY
Ideally, DNA-T would be tested in low concentrations of FCS to retain high 
stability. However, it was unknown if breast cancer cells would retain substantial culture 
growth if incubated with 2% FCS. The growth of MDA-MB-231 cells in media with 
different concentrations of FCS was tested using a SRB assay in order to determine the 
best concentration to use for DNA-T testing (Figure 2). MDA-MB-231 culture growth
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was significantly different at all concentrations of FCS (N = 7, p’s < 0.05). However, 
incubation with 5 and 10% FCS resulted in similar increasing growth at all time points. 
Cells did not grow nearly as well in 2% FCS and the population did not increase from 48 
to 72 hours. Therefore, 5% FCS was chosen to provide stability to DNA-T and allow the 
breast cancer cell cultures to retain a normal amount of growth.
FCS Viability
Time (hours)
□  10% 
^ 2%
Figure 2. MDA-MB-231 population in 10, 5, and 2% FCS. The cell population after 72h 
in 10% FCS was the maximum and was normalized to 100%. This population was used 
to normalize all other treatment groups, * indicates significance vs. 0-time point and A 
indicates significance vs. 10% FCS at a given time point (p’s < 0.05, ANOVA with 
Tukey’s post hoc test). The populations between 2% FCS at 48 and 72 h FCS were not 
different. N = 7 per experiment, 1 experiment.
The viability of both cells lines was accessed after treatment with DNA-T, DOX, 
and DOX loaded into DNA-T using SRB assays (Figure 3). DNA-T alone did not affect 
the survival of MDA-MB-231 or MDA-MB-453 cells, which was expected (N = 9, p’s > 
0.5). The viability of both cell types in DOX and DOX-DNA-T was time- and 
concentration-dependent. Higher concentrations and longer times resulted in more death.
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DOX alone killed more cells after 24 hours than DOX-DNA-T, with significant decreases 
at 2 through 10 gM in MDA-MB-231 and at 1 through 10 gM in MDA-MB-453 (N = 9, 
p’s < 0.005). Cell viability dropped to 46 and 45% in MDA-MB-231 and MDA-MB-453 
cells after 10 gM of DOX exposure for 24 hours, respectively. DOX-DNA-T only 
showed a significant decrease at 5 and 10 gM of DOX in MDA-MB-231 and only at 10 
gM in MDA-MB-453 (N = 9, p’s < 0.05) with 24-hour exposure. The resulting viabilities 
were 76 and 78% in MDA-MB-231 and MDA-MB-453, respectively, after 24-hour 
incubation with 10 gM of DOX-DNA-T. After 48 hours of exposure, DOX also 
decreased viability at lower concentrations, which both cell lines experiencing significant 
decreases at 0.5 through 10 gM (N = 9, p’s < 0.005). DOX-DNA-T treatment for 48 
hours showed a significant decrease in viability at 2 through 10 gM in both cell lines and 
additionally at 1 gM for MDA-MB-231 (N = 9, p’s < 0.005). Both treatments reduced the 
viability of the cell lines down to a similar level after 48-hour 10 gM exposure, with 
survival being approximately 7 to 11%.
Table 1. Acidity of MDA-MB-231 and MDA-MB-453 cultures. Mean pH ± the SD.
Time ____________________ PH____________________
231 453 Media
24h 7.12 ± 0.03 7.47 ± 0.03 7.47 ± 0.02
48h 7.04 ± 0.03 7.42 ± 0.02
MDA-MB-453 seemed more susceptible to DOX alone than MDA-MB-231, with 
lower viability at 1 through 5 gM after 24 hours and at 0.5 through 2 gM after 48 hours. 
Loading DOX into DNA seemed to modulate the differences in viability between the two
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cell lines. Differences in toxicity were not likely due to altered pH between the cell types, 







DOX-loaded DNA Triangle Viability
DOX (mM)
1 = 1  24h 231 
=  24h 453  
=  48h 231 
=  48h 453
Figure 3. Viability of MDA-MB-231 and 453 cells after exposure to (A) DNA-T alone, 
(B) free DOX, and (C) DOX-DNA-T for 24 and 48h. Untreated cell population was 
considered 100% viable and used to normalize the viability of other groups. Treated cell 
population was calculated as a percentage of the control and compared to the control and 
other groups using one-way ANOVA with Tukey’s post hoc test, * p’s < 0.05. N = 3 per 
experiment, 3 experiments.
3.3. APOPTOSIS
DOX exposure produced a much higher rate of total apoptosis compared to DOX- 
DNA-T overall (Figure 4). After 48 hours, 10 pM of DOX resulted in 20% and 51% of
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MDA-MB-231 and MDA-MB-453 cells undergoing apoptosis, respectively, while 10 ^M 
of DOX-DNA-T after 48 hours resulted in 20% and 16% in the same cell lines. For DOX 
alone, apoptosis at both time points and in both cell lines was significantly increased at 5 
and 10 ^M (N = 3, p’s < 0.05). At 2 ^M of DOX, 24- and 48-hour MDA-MB-453, as 
well as 48-hour MDA-MB-231 were significantly higher (N = 3, p’s < 0.01). MDA-MB- 
231 also showed significance at 1 ^M of DOX after 48-hour exposure (N = 3, p’s < 0.05). 
DOX-DNA-T did not induce significant apoptosis at any concentration after 24 hours, 
except for 2 ^M in MDA-MB-453 cells, which was not substantially higher than the 
control. After 48 hours, MDA-MB-453 showed significantly higher apoptosis at 1 
through 10 ^M and MDA-MB-231 at 5 and 10 p,M of DOX-DNA-T (N = 3, p’s < 0.05). 
Example flow cytometry data is shown in Figure 4C and D.
Figure 5 shows confocal images of MDA-MB-231 and MDA-MB-453 cells after 
24- and 48-hour exposure to 10 ^M of DOX and DOX-DNA-T. Results were visually 
comparable to flow data, with cells exposed to DOX alone appearing to have more 
visible red apoptosis staining than DOX-DNA-T treated cells. Cells treated with DOX- 
DNA-T also appeared to have a higher concentration of DOX within them, based on the 
greater fluorescence intensity observed. DOX seemed to be localized in the cytoplasm in 
both cases. Morphological analysis of the cells with DIC imaging (Figure 6) revealed 
more debris in cultures treated with DOX-DNA-T and more blebbing cells in cultures 
treated with DOX alone. Debris in DOX-DNA-T treated cultures were dark and did not 
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Figure 4. Total apoptosis of MDA-MB-231 and MDA-MB-453 cell lines after exposure 
to (A) DOX and (B) DOX-DNA-T for 24 and 48h, quantified using flow cytometry. The 
percentage of cells positive for Annexin V staining were considered apoptotic. Example 
flow cytometry data of (C) 453 cells with no drug exposure and (D) 453 cells after 48h 
DOX exposure. Samples were compared to the control and other groups using one-way 











Control DOX (10 uM) DOX-DNA-T (10 uM)
Figure 5. Confocal images of cells undergoing apoptosis after exposure to 10 gM of 
DOX or DOX-DNA-T. Blue is Hoechst, red is Annexin V, and green is DOX. White 
arrowheads indicate blebbing cells and white-outlined black arrowheads point to 










Control D O X  (10  pM ) D O X -D N A -T  (1 0  u M )
Figure 6. Morphology of cells after exposure to 10 pM of DOX and DOX-DNA-T. White 
arrowheads point to debris in solution and white-outlined black arrowheads point to 
membrane-associated debris. Scale bar is 50 pm, 40x oil objective.
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(A)
231 + 24h DOX + LysoTracker 453 + 24h DOX + LysoTracker
XY YZ XY YZ
(B)
231 +24h DOX-DNA-T 
XY
+ LysoTracker 453 + 24h DOX-DNA-T + LysoTracker
Figure 7. Localization of (A) DOX and (B) DOX-DNA-T in MDA-MB-231 (left) and 
MDA-MB-453 (right) after 24h. Blue is Hoechst, green is DOX, and red is LysoTracker. 
Cells were treated with 2 gM of either free DOX or DOX-DNA-T for 24h. Scale bar is 10 
gm in XY, XZ, and YZ. Images are 5x zoomed in areas from a 60x oil objective field. Z- 
stacks were imaged 25 gm around the focal point, with a 1 gm step. Full field images can 
be found in the supplementary data.
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3.4. UPTAKE
3.4.1. Subcellular Localization. DOX alone localized into the lysosome based 
on green DOX fluorescence co-localizing with the red LysoTracker in both cell lines 
(Figure 7). DOX-DNA-T were expected to be subcellularly localized in the lysosome, 
mitochondria, or nuclei. However, DOX-DNA-T was dispersed through the cell 
cytoplasm, had low nuclear localization, and had relatively low lysosomal localization 
compared to DOX alone. MDA-MB-453 seemed to have lower DOX-DNA-T lysosomal 
localization compared to MDA-MB-231, which seemed to increase from 24 to 48 hours. 
MDA-MB-453 had noticeably smaller lysosomes compared to MDA-MB-231. 
Localization did not seem to differ substantially between 24 and 48 hours and neither free 
DOX nor DOX-DNA-T seemed to localize within the mitochondria (Appendix Figures 1­
8).
3.4.2. Time-Dependent Uptake. The internalization of DOX and DOX-DNA-T 
was determined over the course of 0 to 4 hours and after 24 and 48 hours using flow 
cytometry (Figure 8). Select time points (1, 24, and 48 hours) were chosen be imaged 
using a confocal microscope for visual comparison. In both cell lines, DOX uptake was 
significant from 1 to 4 hours and after 24 and 48 hours (N = 3, p’s < 0.005). DOX uptake 
was significantly different between 24- and 48-hour incubation (N = 3, p’s < 0.05). DOX 
uptake after 24 and 48 hours was not different between the two cell lines (N = 3, p’s > 
0.05). Internalization during 30 minutes to 4 hours and after 24 and 48 hours was 
significant after DOX-DNA-T exposure (N = 3, p’s < 0.05). DOX-DNA-T uptake was 
the same in MDA-MB-453 cells between 24 and 48 hours (N = 3, p’s > 0.5). Although 
the average fluorescence of MDA-MB-231 cells was higher after 48-hour DOX-DNA-T
treatment compared to 24-hour treatment, the two time points were not significantly 
different (N = 3, p’s > 0.1). MDA-MB-231 cells did show significantly higher 
fluorescence after incubation with DOX-DNA-T compared to free DOX at both time 
points and to DOX-DNA-T treated MDA-MB-453 cells after 48 hours (N = 3, p’s <
0.05). After 24- and 48-hour incubation, MDA-MB-453 cells had similar DOX-DNA-T 
fluorescence compared to 48-hour DOX (N = 3, p’s > 0.5). During shorter periods of 
time, internalization was similar between the free drug and loaded drug in both cell lines 
(N = 3, p’s > 0.1 time point vs. time point), though DNA-T averages were lower at every 
time point. MDA-MB-453 internalized more DOX when it was loaded into DNA-T 
compared to MDA-MB-231 during the shorter duration incubation, after 2 and 4 hours (N 
= 3, p’s < 0.05). Confocal images confirmed that DOX-DNA-T uptake at 1 hour was 
similar to DOX alone and was higher than free DOX after 24 and 48 hours (Figure 9). 
DOX-DNA-T had a similar diffused appearance after 1, 24, and 48 hours at 2 pM. 
However, DOX appeared to be diffused throughout cells after 1 hour and collect into 
lysosomes after 24 and 48 hours in MDA-MB-231 and after 48 hours in MDA-MB-453.
3.4.3. Energy Inhibition. Inhibition studies were carried out with 1-hour drug 
incubations as uptake in the first 4 hours did not plateau and 1 hour was the first time 
point where all conditions were significantly different from the control. Cells incubated 
with metabolic inhibitors and DOX or DOX-DNA-T are shown in Figure 10. The mixture 
of metabolic inhibitors prevented energy-dependent internalization by depleting cellular 
ATP levels. Sodium azide and antimycin A interfere with the mitochondrial electron 
transport chain [32, 33], while sodium fluoride inhibits glycolysis [34]. Cells were 
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Figure 8. Time-dependent uptake of 2 pM of (A) DOX or (B) DOX-DNA-T. The small 
graph insert is a magnified 0 to 4h time scale. Significance vs. control is indicated with a 
colored *, color corresponding to the line color, p’s < 0.05. A A indicates significance 
between cell lines at a given time point, p’s < 0.05. Analyzed in CytExpert with 525/40 
nm filter set (505-545 nm range). Significance between groups and vs. the controls were 
determined using one-way ANOVA with Tukey’s post hoc test. N = 3 experiments, with 















Figure 9. Time-dependent uptake microscopy of DOX or DOX-DNA-T after 1, 24, and 
48h. Drug concentration was 2 pM. Scale bar is 50 pm, 40x oil objective.
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cytometer. DOX fluorescence inside either cell line did not significantly differ after cells 
were pre-incubated with a metabolic inhibitor cocktail, indicating that DOX 
internalization was not energy dependent and through diffusion (N = 3, p’s > 0.5). Cell 
fluorescence after treatment with the metabolic inhibitor and DOX-DNA-T was 
significantly lower than without inhibitor (N = 3, p’s < 0.05). Energy inhibition reduced 
MDA-MB-231 fluorescence to 85% of uninhibited fluorescence and MDA-MB-453 to 
75%. This indicates that DOX-DNA-T required energy to be internalized. Differences are 
not as apparent in confocal images for energy inhibited samples or those treated with 
other inhibitors, likely because fewer cells could be analyzed than with flow cytometry.
3.4.1. Clathrin Inhibition. Both MDA-MB-231 and MDA-MB-453 showed 
similar trends after incubation with several clathrin-dependent endocytosis inhibitors 
(Figure 11). The clathrin inhibitors used interfere with clathrin plasma membrane 
distribution and clathrin-coated pits. Sucrose causes clathrin to form microcages, rather 
than the normal lattice structures that are required to form endocytic vesicles [35]. 
Chlorpromazine causes clathrin and the AP-2 protein required for lattice assembly to 
relocate from the plasma membrane to internal vesicles [36]. MDC functions by 
stabilizing clathrin-coated pits and limits formation of new lattices [37, 38]. Sucrose and 
MDC decreased internalization of DOX-DNA-T to a higher degree than Chlorpromazine, 
though all showed significant decreases (N = 3, p’s < 0.05). Sucrose decreased 
fluorescence to 31 and 35% of the uninhibited fluorescence in MDA-MB-231 and MDA- 
MB-453, respectively. MDC reduced fluorescence to 61% in MDA-MB-231 and 76% in 
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Figure 10. Energy-dependent uptake inhibition of 2 pM of DOX or DOX-DNA-T after 
1h. Uninhibited controls after 1h incubation were used to normalize the data set and 
inhibited samples were compared to the control using one-tailed t-tests, p’s < 0.05. N = 3. 
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Figure 11. Clathrin-dependent uptake inhibition of 2 pM DOX-DNA-T after 1h. 
Uninhibited control fluorescence of DOX-DNA-T after 1h incubation was used to 
normalize the data set and inhibited samples were compared to the control using one­
tailed t-tests, p’s < 0.05. N = 3. Scale bar is 50 pm, 40x oil objective.
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respective cell lines. Sucrose may have decreased fluorescence more than other inhibitors 
as it is not as specific [31].
3.4.2. Caveolae Inhibition. Caveolin-dependent endocytosis was inhibited with 
filipin and nystatin pre-incubation (Figure 12). Both sequester and deplete cholesterol 
from the membrane, which is required for caveolar invagination and lipid-raft-dependent 
internalization [31, 39]. Filipin and nystatin significantly inhibited DOX-DNA-T uptake 
in both cell lines (N = 3, p’s < 0.05). MDA-MB-231 fluorescence was reduced to 83% of 
the control using filipin and to 71% using nystatin. MDA-MB-453 incubation with filipin 
reduced cell fluorescence to 63% and nystatin reduced it to 71%.
3.4.3. Macropinocytosis Inhibition. Macropinocytosis inhibitors significantly 
reduced the fluorescence of cells (Figure 13). Cyt D alters the polymerization of actin 
[40], on which macropinocytosis is dependent [41]. EIPA inhibits Na+/H+ exchange, 
insulting in alterations in submembrane pH that affect actin remodeling GTPases [42]. 
MDA-MB-231 cell fluorescence was reduced to 80% of the control using EIPA and to 
73% using Cyt D. With MDA-MB-231, EIPA reduction was significant (N = 3, p < 0.05) 
but Cyt D was slightly out of the significance range (N = 3, p = 0.07), likely due to higher 
variation. Both inhibitors significantly reduced the fluorescence in MDA-MB-453 cells, 
with EIPA decreasing it to 83% and with Cyt D to 73% (N = 3, p’s < 0.05).
4. DISCUSSION
The flexible shape and enhanced tumor retention, along with biocompatibility, 
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Figure 12. Caveolin-dependent uptake inhibition of 2 pM DOX-DNA-T after 1h. 
Uninhibited control fluorescence of DOX-DNA-T after 1h incubation was used to 
normalize the data set and inhibited samples were compared to the control using one­
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Figure 13. Macropinocytosis inhibition of 2 gM of DOX-DNA-T after 1h. Uninhibited 
control fluorescence of DOX-DNA-T after 1h incubation was used to normalize the data 
set and inhibited samples were compared to the control using one-tailed t-tests, p’s < 
0.05. N = 3. Scale bar is 50 gm, 40x oil objective.
the potential to overcome resistance and reduce systematic toxicity [13, 14], their exact 
cellular uptake mechanism was not well understood. Uptake mechanism and subcellular 
localization influence drug delivery efficacy and need to be considered when designing 
drug carriers. The stability of DNA nanostructures in physiological environments has 
been a concern in vivo due to endogenous nucleases [43]. Despite concerns, DNA 
nanostructures maintain their integrity in cell medium for up to 12 hours at the 
concentration of FCS tested, enough time for adequate circulation and cellular uptake 
[44, 45].
The anticancer efficacy of drug-loaded DNA origami has been shown to be shape- 
dependent in vivo [18]. In our study, the decrease in viability after exposure to DOX and 
DOX-DNA-T was significant and differed between time-points and concentrations. DOX 
alone was more toxic overall. DOX-DNA-T seemed to have a delayed toxicity in the cell 
lines, based on both viability and apoptosis analyses. This may have been due to the 
origami slowly releasing the DOX. Since DNA nanostructures sequester loaded 
anthracyclines and have a delayed killing effect, systemic exposure and off-targeting can 
be reduced as the origami have time to passively accumulate in tumors. Interestingly, 
DOX-DNA-T seemed to modulate the differences in DOX toxicity between the two cell 
lines, with both cell lines having a very similar decrease in viability. Extending the time 
points analyzed would likely reveal higher efficiency in DOX-DNA-T killing as cell 
death seemed delayed. There was a sharp decrease in viability at higher concentrations of 
DOX-DNA-T after 48 hours and this trend is likely to continue. Zeng et al. were able to 
show similar killing efficiencies in MDA-MB-231 cells between DOX and several DOX- 
loaded DNA origami shapes after 96 hours [15].
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Induction of apoptosis at most concentrations and time points was consistent with 
the decreases observed in viability. DOX-DNA-T treatment resulted in less apoptosis 
based on flow cytometry and microscopy analysis. However, at higher concentrations and 
longer times, where DOX and DOX-DNA-T viability reduction was similar, the two 
treatments did not result in similar amounts of apoptosis. This indicates that DOX-DNA- 
T may be killing cells by a different mechanism, or that cells exposed to DOX-DNA-T 
apoptosis faster at these concentrations and were dead before the analysis occurred, 
resulting in lower total apoptosis recorded. It is also possible that DOX-DNA-T induced 
more necrosis rather than just apoptosis. Cultures had more debris after treatment with 
DOX-DNA-T compared to DOX alone. When cells undergo necrosis, they rapidly lose 
membrane integrity and cellular contents are released into the surroundings [46], which 
may be the cause of the debris and potential faster cell death observed. However, further 
experimentation is required to differentiate between death mechanisms.
Although DNA-T sequesters DOX initially, the drug slowly dissociates from the 
complexes. Zeng et al. showed that there was not a significant difference in DOX release 
from origami between 6.6 and 7.4 pH [15]. DOX release was around twice as high at 4.5 
pH, the pH of lysosomes. The differences in drug release at different pH likely play a role 
in drug dynamics within cells, especially if the carrier interacts with lysosomes.
However, the differences observed in toxicity were likely not due to differences in media 
pH, as all cell culture media pH was close to neutral, even after 48 hours of cell growth.
As DOX is a small molecule, it was expected that the drug would not be localized 
in certain areas within cells, but diffuse evenly throughout the cytoplasm. Dispersed 
DOX would also have a higher chance to attack the nucleus than if it were trapped in
specific areas of the cells, which would explain the higher killing. After 1-hour 
incubation DOX appeared to be diffused throughout the cells. However, it was found that 
free DOX localized into lysosomes after 24 and 48 hours. Along with time-dependent 
localization, DOX localization appeared to be concentration dependent. DOX was more 
evenly distributed in the cells at the 10 pM concentration used for apoptosis analysis 
compared to the 2 pM used for subcellular localization. Cells may be able to pack DOX 
into lysosomes to sequester the drug, if the concentration is low enough or the exposure 
time is shorter. This mechanism seems likely, as DOX enters into cells by diffusion and 
would not be localized within the lysosomes after endocytosis and endosome evolution 
into lysosomes. DOX being diffused in cells after 1 hour and appearing to become 
localized into the lysosomes overtime supports this. This is also in agreement with 
previous work which has shown DOX can be trapped inside synthetic liposomes that 
have a low internal pH (4.6) compared to the environment (7.5) [47]. It has been 
speculated that DOX may become trapped inside membranes with low internal pH due to 
DOX protonation and gaining charge [47]. Gaining charge would prevent DOX from 
diffusing, as charged molecules are unable to pass through lipid membranes [48].
Without a sequestering mechanism, DOX would likely just diffuse out of the 
lysosomes if pushed inside. MDA-MB-453 cells had noticeably smaller lysosomes, and 
were also more susceptible to DOX at concentrations in the middle of the tested range. At 
high concentrations or long periods of exposure, it may be the case that cells do not have 
sufficient lysosomal capacity or free lysosomal protons to sequester DOX. MDA-MB- 
453 cells may reach their sequestering limit before MDA-MB-231 and thus die at lower 
concentrations of the drug. It is unknown what the threshold concentration of DOX might
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be for this mechanism in live cellular systems. A previous study has shown nuclear 
localization after 72 hours using the same concentration of DOX (2 pM) [15]. It is 
possible more DOX was able to enter cells after 72-hour incubation and avoided being 
sequestered. However, epifluorescent imaging or fixing cells may have produced 
artifacts, resulting in the appearance of nuclear localization. Epifluorescence 
microscopes capture light from the entire cell, so fluorescence inside the cytoplasm above 
the nucleus can appear as nuclear localization. Fixation can also result in artificial entry 
of compounds into cells [49]. Confocal microscopy utilizes lasers to take images of 
singular planes within cells, allowing clearer images to be captured.
The localization of DOX was altered by loading it into DNA-T. DOX-DNA-T 
was expected to be localized within cell lysosomes, the opposite of the expected outcome 
for DOX alone. However, relatively few lysosomes showed localization with DOX- 
DNA-T compared to DOX alone. DOX-DNA-T was instead more evenly spread 
throughout the cells at both time points and concentrations imaged. This may have been 
due to the higher concentration of internalized DOX facilitated by DNA-T. As 
endosomes evolve into lysosomes, they fuse with vesicles from the Golgi apparatus and 
become acidified [50]. During acidification and when lysosomes maintain their low pH 
by pumping in protons, if acidification is prevented by molecules acting as “proton 
sponges,” lysosomes will keep transporting protons into themselves [51]. However, the 
lysosome will also begin to transport chloride ions inside in order to maintain their 
charge, which will cause water to influx to the higher concentration, leading to lysosomal 
swelling and bursting due to osmotic pressure [51]. High concentrations of DOX or DNA 
origami may act as proton sponges, as DOX becomes protonated inside lysosomes and
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DNA has a negatively charged backbone. It is likely that DOX-DNA-T is originally 
localized in endosomes after endocytosis. DOX and DOX-DNA-T may be released from 
the endosomes due to bursting. Bursting lysosomes release toxic substances and may 
attribute to the sharp decline in cell health when treated with DOX-DNA-T, as lysosomal 
swelling and lysis is associated with increased cytotoxicity [51, 52]. This might explain 
why MDA-MB-453 seemed to have lower lysosomal localization of DOX-DNA-T, if 
they have smaller lysosomal capacity and their lysosomes with internalized DOX-DNA-T 
lyse quickly. This process may result in higher cellular DNA damage and cause the cells 
to die faster or necrose, preventing the total apoptotic population from being detected. 
Generally, necrosis is less desirable in vivo than apoptosis because of the release of 
inflammatory substances and wastes from unorganized cell death [46]. Nonetheless, 
DNA-T allows DOX to avoid sequestering by lysosomes initially. After 48 hours, DOX- 
DNA-T lysosomal localization appeared to increase in the cells but this fluorescence may 
have been DOX dissociated from the DNA-T.
Localization and apoptosis imaging studies revealed higher fluorescence of 
internalized DOX when loaded into DNA-T. Uptake of DOX and DOX-DNA-T was 
analyzed at 2 pM to reveal the differences between internalization quantity and route. 
Although the viability of the two cell lines differed after 24- and 48-hour DOX exposure, 
their DOX internalization appeared to be reaching a threshold. This may have been due to 
DOX diffusion eliminating the concentration gradient between the internal and external 
environment of the cells, allowing only so much DOX to be internalized. Binding of 
DOX to internal cell structures or entrapment in lysosomes would decrease the 
concentration of free DOX inside cells and reestablish a small concentration gradient
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overtime, leading to the slight upward trend observed over long exposure periods [29]. 
While uptake between 0 and 4 hours was similar between the free and carried drug, 
DOX-DNA-T showed higher uptake at 24 and 48 hours, indicating DNA-T facilitated 
drug entry. Since internalized DOX was already bound in DNA-T, this may have also 
encouraged DOX diffusion from external DNA-T that released DOX into the culture 
media. Enhanced accumulation may aid in killing cancers that have developed resistance 
to the drug as exposure time and dose is increased [14]. MDA-MB-453 showed lower 
uptake of DOX-DNA-T after 24 and 48 hours compared to MDA-MB-231, even though 
their viability was similar after DOX-DNA-T exposure. This may have been due to 
MDA-MB-453 having a lower ability to localize DOX-DNA-T in lysosomes or other 
factors such as differences in metabolic function between the cell lines, different uptake 
mechanisms being damaged after longer exposure to DOX, or different methods of DOX- 
DNA-T expulsion.
DOX internalization by diffusion was confirmed as fluorescence was not 
significantly different from metabolic-inhibited internalization. Cells treated with 
metabolic inhibitors actually showed slightly higher DOX uptake on average. This is 
consistent with a proposed mechanism which states that DOX enters by diffusion and is 
actively pumped out of cells [28, 30]. Energy-dependent pumps would not function in the 
presence of metabolic inhibitors and cause DOX concentration to be increased inside 
cells.
DOX-DNA-T internalization appeared to be by a different mechanism than free 
DOX. Inhibition of all pathways studied resulted in decreased fluorescence of 
internalized DOX when it was carried by DNA-T. Unlike free DOX, incubation with
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metabolic inhibitors reduced internalized DOX-DNA-T significantly, indicating a 
dependence on energy. The highest decrease in fluorescence was observed using clathrin 
and caveolin/lipid-raft inhibitors, indicating that DOX-DNA-T uptake is reliant on 
various endocytosis mechanisms. Negatively charged DNA nanostructures likely interact 
with positively charged membrane molecules on the cell surface and induce endocytosis. 
It must also be considered that many pharmacological inhibitors effect multiple pathways
[31]. For instance, MDC interacts with transglutaminases, which are important for actin 
assembly [31, 37]. Sucrose is not very specific and can block the formation of membrane 
invaginations not coated with clathrin [31]. EIPA may alter endocytosis involving 
clathrin and it has been suggested that Cyt D may block most forms of endocytosis [31, 
53]. Thus, using complementary inhibitors provides strong support for the use of various 
specific pathways. To confirm that DNA origami does not prefer specific pathways, 
siRNA inhibition of essential proteins utilized in each pathway would be necessary. It is 
also a possibility that DNA-T could be labeled separately from DOX to further analyze 
the uptake, but sources have indicated that conjugated dyes may become dissociated from 
DNA after internalization [54]. Uptake inhibition of DOX-DNA-T may not have been as 
efficient as possible due to DOX being released from DNA origami in solution and 
entering cells by diffusion.
Along with siRNA testing, further studies with various nanostructure shapes and 
sizes will enable us to identify if DNA origami is preferentially taken up by a pathway 
dependent on specific proteins and the optimal geometry to achieve the highest transport 
efficiency and cellular uptake. It would be most ideal to deploy a quantitative structure 
activity relationship (QSAR) analysis to test different shapes and sizes of DNA origami
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for finding a relationship between structure and function. The most effective 
nanostructure derived from such an analysis can be used in a targeted delivery system. 
One such target could be the urokinase-type plasminogen activator receptor (uPAR), 
which is upregulated in some TNBCs [55]. The TNBC cell lines MDA-MB-231 (high 
uPAR expression) and MDA-MB-453 (low uPAR) were tested to further this goal in 
future studies. The functionalization capacity of DNA origami holds many potentials. 
However, despite the unknowns that still need to be elucidated, DNA origami research 
may lag due to concerns about its stability.
5. CONCLUSIONS
DNA-T is able to facilitate DOX internalization by an energy-dependent 
endocytosis mechanism. The carrier is able to circumvent differences in DOX toxicity 
between cell lines and DOX sequestering in lysosomes. The toxicity of DOX was delayed 
when loaded into DNA-T, likely due to slow release from the nanostructures. The 
mechanism of cell death may differ when using DNA-T as a carrier for DOX. The higher 
concentration of DOX internalized with DNA-T indicates therapeutic concentrations can 
be lowered with similar effects, as long as exposure time is sufficient.
Cancer is a devastating disease and many chemotherapies leave patients 
debilitated, especially in cases like TNBC where harsh treatment is the only option. Drug 
delivery to tumor sites can decrease the harm chemotherapies inflict on healthy tissue and 
decrease overall patient morbidity. More treatment options give patients and doctors 
alternatives which may be better suited to individual care. The mechanism of DNA
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nanostructure uptake is now better understood, allowing these factors to be considered 
when delivering drugs and developing DNA origami as a drug carrier system.
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DNA is a highly therapeutic molecule, with the potential to alter cell protein 
expression and carry drugs into cells. A large number of DNA delivery tools have been 
explored and it is apparent that delivery technologies will continue to develop in order to 
improve overall patient outcome. DNA nanostructures are a promising delivery method 
due to programmability and modification. They facilitate drug delivery into cells, showed 
a delayed toxicity that allows cells to uptake ample amounts of the complex, and require 
energy to be internalized most efficiently. Loading DOX into DNA origami can reduce 
systemic exposure by sequestering the drug. Facilitation of DOX entry using DNA 
origami may allow therapeutic doses to be lowered with adequate exposure time. 
However, the optimal size and shape of origami has yet to be determined. Further studies 
need to be conducted in order to discover the optimal geometry for drug delivery and to 
increase origami stability for use in vivo. Full understanding of the uptake mechanism 
will allow better design of DNA origami as a drug carrier system.
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APPENDIX
PAPER II SUPPLEMENTARY FIGURES
Supplementary Figure 1. 24h DOX localization in MDA-MB-231. Blue is Hoechst, green 
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of 
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 2. 24h DOX localization in MDA-MB-453. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 3. 24h DOX-DNA-T localization in MDA-MB-231. Blue is 
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale 
bar is 10 pm.
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Supplementary Figure 4. 24h DOX-DNA-T localization in MDA-MB-453. Blue is 
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale 
bar is 10 pm.
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Supplementary Figure 5. 48h DOX localization in MDA-MB-231. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 6. 48h DOX localization in MDA-MB-453. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 7. 48h DOX-DNA-T localization in MDA-MB-231. Blue is 
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale 
bar is 10 pm.
118
Supplementary Figure 8. 48h DOX-DNA-T localization in MDA-MB-453. Blue is 
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale 
bar is 10 pm.
119
BIBLIOGRAPHY
[1] Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. 
Nat Rev Drug Discov 2017; 16(6): 387-99.
[2] Burney TJ, Davies JC. Gene therapy for the treatment of cystic fibrosis. Appl Clin 
Genet 2012; 5: 29-36.
[3] Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene 
therapy approaches to sickle cell disease. Blood 2016; 127(7): 839-48.
[4] Dickey AS, La Spada AR. Therapy development in Huntington disease: From 
current strategies to emerging opportunities. Am J Med Genet A 2018; 176(4): 
842-61.
[5] Al-Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent 
progress. AAPS J 2009; 11(4): 671-81.
[6] Korzh V, Strahle U. Marshall Barber and the century of microinjection: from 
cloning of bacteria to cloning of everything. Differentiation 2002; 70(6): 221-6.
[7] Xia J, Martinez A, Daniell H, Ebert SN. Evaluation of biolistic gene transfer 
methods in vivo using non-invasive bioluminescent imaging techniques. BMC 
Biotechnol 2011; 11: 62.
[8] Tomizawa M, Shinozaki F, Motoyoshi Y, et al. Sonoporation: Gene transfer using 
ultrasound. World J Methodol 2013; 3(4): 39-44.
[9] Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. Ultrasound- 
mediated transfection of mammalian cells. Hum Gene Ther 1996; 7(11): 1339-46.
[10] Luft C, Ketteler R. Electroporation Knows No Boundaries: The Use of 
Electrostimulation for siRNA Delivery in Cells and Tissues. J Biomol Screen 
2015; 20(8): 932-42.
[11] Roy I, Mitra S, Maitra A, Mozumdar S. Calcium phosphate nanoparticles as novel 
non-viral vectors for targeted gene delivery. Int J Pharm 2003; 250(1): 25-33.
[12] Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid- 
mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 1987; 84(21): 
7413-7.
120
[13] Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from 
molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157(2): 195-206.
[14] Merten OW, Gaillet B. Viral vectors for gene therapy and gene modification 
approaches. Biochem Eng J 2016; 108: 98-115.
[15] Wu D, Wang L, Li W, Xu X, Jiang W. DNA nanostructure-based drug delivery 
nanosystems in cancer therapy. Int J Pharm 2017; 533(1): 169-78.
[16] Ramakrishnan S, Ijas H, Linko V, Keller A. Structural stability of DNA origami 
nanostructures under application-specific conditions. Comput Struct Biotechnol J 
2018; 16: 342-9.
[17] Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: 
incorporating size, shape and triggered release into nanoscale drug carriers. 
Expert Opin Drug Deliv 2010; 7(4): 479-95.
[18] Zhang Q, Jiang Q, Li N, et al. DNA origami as an in vivo drug delivery vehicle 
for cancer therapy. ACS Nano 2014; 8(7): 6633-43.
[19] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 
185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[20] Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for 
targeted therapy. Pharmacogenomics 2017; 18(17): 1595-609.
[21] Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J 
Med 2010; 363(20): 1938-48.
[22] Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in 
triple negative breast cancer. Pharmacol Ther 2019.
[23] Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA 2019; 321(3): 
288-300.
[24] Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast 
cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast 
Cancer 2011; 18(3): 165-73.
[25] Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 
1997; 54 Suppl 4: 1-7.
121
[26] Agudelo D, Bourassa P, Berube G, Tajmir-Riahi HA. Intercalation of antitumor 
drug doxorubicin and its analogue by DNA duplex: structural features and 
biological implications. Int J Biol Macromol 2014; 66: 144-50.
[27] Kim KR, Kang SJ, Lee AY, et al. Highly tumor-specific DNA nanostructures 
discovered by in vivo screening of a nucleic acid cage library and their 
applications in tumor-targeted drug delivery. Biomaterials 2019; 195: 1-12.
[28] Halley PD, Lucas CR, McWilliams EM, et al. Daunorubicin-Loaded DNA 
Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia 
Model. Small 2016; 12(3): 308-20.
[29] Zeng Y, Liu J, Yang S, et al. Time-lapse live cell imaging to monitor doxorubicin 
release from DNA origami nanostructures. J Mater Chem B 2018; 6(11): 1605-12.
122
VITA
Natalie Jordan Holl graduated from Lone Jack High School and received her 
Associate of Science degree from Northwest Missouri State University in May 2016. She 
received a Bachelor of Science in Biological Sciences from the Missouri University of 
Sicence and Technology in December 2018. During her final semester of her 
undergraduate degree, she was dual-enrolled as a graduate student and worked in Dr. 
Yue-Wern Huang’s lab. The following spring, she began work as a full-time master’s 
student. She received her master’s degree in Applied and Environmental Biology from 
the Missouri University of Science and Technology in December 2020.
